
[All ETDs from UAB](#)

[UAB Theses & Dissertations](#)

1996

An epidemiologic investigation of the possible association between maternal diabetes and maternal hypertension and placental infection with *Ureaplasma urealyticum*.

Richard Joseph Sinsky
University of Alabama at Birmingham

Follow this and additional works at: <https://digitalcommons.library.uab.edu/etd-collection>



Part of the [Public Health Commons](#)

Recommended Citation

Sinsky, Richard Joseph, "An epidemiologic investigation of the possible association between maternal diabetes and maternal hypertension and placental infection with *Ureaplasma urealyticum*." (1996). *All ETDs from UAB*. 6101.

<https://digitalcommons.library.uab.edu/etd-collection/6101>

This content has been accepted for inclusion by an authorized administrator of the UAB Digital Commons, and is provided as a free open access item. All inquiries regarding this item or the UAB Digital Commons should be directed to the [UAB Libraries Office of Scholarly Communication](#).

INFORMATION TO USERS

This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer.

The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction.

In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion.

Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book.

Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order.

UMI

A Bell & Howell Information Company
300 North Zeeb Road, Ann Arbor, MI 48106-1346 USA
313/761-4700 800/521-0600

AN EPIDEMIOLOGIC INVESTIGATION OF THE POSSIBLE ASSOCIATION
BETWEEN MATERNAL DIABETES AND MATERNAL HYPERTENSION
AND PLACENTAL INFECTION WITH
Ureaplasma urealyticum

by

RICHARD J. SINSKY

A DISSERTATION

Submitted in partial fulfillment of the requirements for the degree of Doctor of Public Health
in the Department of Epidemiology, School of Public Health
The University of Alabama at Birmingham

BIRMINGHAM, ALABAMA

1996

UMI Number: 9734564

UMI Microform 9734564
Copyright 1997, by UMI Company. All rights reserved.

**This microform edition is protected against unauthorized
copying under Title 17, United States Code.**

UMI
300 North Zeeb Road
Ann Arbor, MI 48103

SCHOOL OF PUBLIC HEALTH
UNIVERSITY OF ALABAMA AT BIRMINGHAM
ABSTRACT OF DISSERTATION

Degree Doctor of Public Health Major Subject Epidemiology


Name of Candidate Richard Joseph Sinsky


Title An Epidemiologic Investigation of the Possible Association Between Maternal Diabetes and Maternal Hypertension and Placental Infection with *Ureaplasma urealyticum*


Ureaplasma urealyticum is a cell wall free bacterium found in the lower urogenital tract of up to 83.1% of all sexually active adult women. Up to 90% of all pregnant women have also been shown to be infected with *U. urealyticum* through endocervical cultures, whereas only up to 15% of pregnant women have cultural evidence of ureaplasma infection of the placenta. A cross-sectional study was conducted at the University Hospital of the University of Alabama at Birmingham, which included 645 of 815 (79%) Cesarean section deliveries with intact fetal membranes. The purpose of this study was to evaluate the association between maternal diabetes, maternal hypertension, and placental infection with *Ureaplasma urealyticum*. Using multivariate logistic regression to control for confounding factors, it was found that in this population, the odds ratio for placental infection, given maternal diabetes, was 1.39 (CI₉₅ = 0.48, 4.00), indicating that there was no association between maternal diabetes and placental infection with *U. urealyticum*. Odds ratios of 0.29 (CI₉₅ = 0.12, 0.68) for any diagnosis of hypertension, 0.52 (CI₉₅ = 0.13, 1.99) for chronic hypertension, 0.28 (CI₉₅ = 0.11, 0.76) for pregnancy-induced (acute) hypertension, 0.23 (CI₉₅ = 0.02, 2.77) for acute superimposed on chronic hypertension, and 0.29 (CI₉₅ = 0.12, 0.70) for a measured abnormal increase in maternal blood pressure during pregnancy, indicate a negative association between at least some forms of hypertension and placental infection with *Ureaplasma urealyticum*. Whether this effect is due to a reduction in the prevalence of *Ureaplasma* infection in the lower genital tract prior to pregnancy or to a suppression of the progression of infection during the pregnancy could not be determined in this study. However, there is evidence,

both pathologic and in the form of quantitative measurements, that there is a reduction of blood flow to the placenta in the presence of hypertension during pregnancy, and this may be one possible explanation for the results found in this study.

Abstract Approved By:



Committee Chair


Dean, Academic Affairs


Dean, School of Public Health

7/25/96

Date 1/9/97

Date 1/10/97

Date

ACKNOWLEDGMENTS

I would like to take this opportunity to acknowledge all of those individuals who had a hand in bringing this dissertation into being.

First and foremost, I extend appreciation to my committee members, Dr. Rodney Go, Department of Epidemiology, School of Public Health, who was the last of a long line of Committee Chairmen; Dr. Laura Perkins, Department of Biostatistics, School of Public Health; Dr. Robert Goldenberg, Department of Obstetrics and Gynecology; and Dr. Lynne Wagenknecht, currently at the Department of Public Health Sciences, Bowman-Gray School of Medicine. A very special thanks goes to Dr. Gail Cassell, who took a chance on a former microbiologist who walked in off the street and asked for a chance to continue to work in microbiology without really working in it.

I would also like to thank Mary DuBard and Suzanne Cliver, Department of Obstetrics and Gynecology, without whom I would have been unable to get the information from the OBAR database for validation and analysis.

Finally, I must also acknowledge Karen Baldus, Donna Crabbe, Lynne Duffey, Wilma Hamrick, and Terri Schmidt for checking and rechecking my data entry, as well as tracking down some of the missing information in the medical and microbiological records.

TABLE OF CONTENTS

	<u>Page</u>
ABSTRACT.....	ii
ACKNOWLEDGMENTS.....	iii
LIST OF TABLES.....	vi
LIST OF FIGURES.....	viii
 CHAPTER	
1 INTRODUCTION.....	1
Biology/Ecology of the Ureaplasmas.....	1
Association with Various Conditions/Diseases.....	3
<u>Ureaplasma</u> Infection in the Upper and Lower Urogenital Tract.....	3
<u>Ureaplasma</u> and Pregnancy Outcomes.....	4
<u>Ureaplasma</u> Infection in Fetuses and Infants.....	4
Serovar Associations with Various Conditions/Diseases.....	5
Risk Factors for Infection.....	6
Infections in Infants.....	6
Infections in Children.....	8
Sexual Activity and Infection in Adults.....	8
Hormonal Influence on Infection Rates in Females.....	10
Other Factors.....	11
Diabetes.....	11
Hypertension.....	13
2 RATIONALE	17
Diabetes	17
Hypertension	18
Hypotheses	19
3 METHODS	20
Study Design	20
Power Calculations	21
Data Collection	22

TABLE OF CONTENTS (Continued)

CHAPTER	<u>Page</u>
3 Infection Status	22
Maternal Characteristics	26
Validation of Complication Status	27
Data Analysis	27
4 RESULTS	29
Comparison of Study Population Groups	29
Validation of Complication Status	39
Risk of Placental Infection with <u>Ureaplasma urealyticum</u>	39
Multivariate Analysis for the Prediction of Placental Infection with <u>Ureaplasma</u>	41
5 DISCUSSION	54
Diabetes	54
Hypertension	55
Additional Findings	56
Sexual Activity Prior to and During Pregnancy	58
Antibiotic Treatment Prior to or During Pregnancy	59
Control of Medical Condition	59
Comparability to the General Population	59
6 SUMMARY	61
LITERATURE CITED	63
APPENDIX	
1 POWER CURVES.....	73
2 OBAR DATA SHEETS.....	78

LIST OF TABLES

<u>Table</u>	<u>Page</u>
1 Isolation rates (percent) of <u>Ureaplasma urealyticum</u> from the conceptus of spontaneous and induced abortions	4
2 Development of chronic lung disease (CLD) in low birthweight infants by <u>Ureaplasma</u> status	6
3 Serotypes of <u>U. urealyticum</u> found in association with various conditions	7
4 Percent Ureaplasma infection in men and women as a function of sexual activity and contraceptive practices	9
5 Endocervical infection rates in pregnant women of various racial groups.....	10
6 White classification of diabetes in pregnant women	14
7 Infection rates (percent) of low- and high-risk pregnancies of diabetic and non-diabetic women	17
8 Characteristics of the mothers and infants enrolled into the study population through December 31, 1989	22
9 Estimated study size and characteristics	23
10 Power calculations for estimated study population (N = 573), with a 2-fold increase in the proportion infected.....	23
11 Incubation conditions for culture media and organisms	25
12 Population characterization for University Hospital deliveries between October 26, 1987 and December 31, 1990	31
13 Comparison of maternal characteristics of women experiencing either a vaginal delivery or a Cesarean section with ruptured fetal membranes	33
14 Comparison of maternal characteristics of women experiencing either a vaginal delivery or a Cesarean section with intact fetal membranes	35

LIST OF TABLES (Continued)

<u>Table</u>	<u>Page</u>
15 Comparison of maternal characteristics of women experiencing a Cesarean section delivery with or without intact membranes	37
16 Population characterization of women eligible for enrollment into the study between October 27, 1987 and December 31, 1990	40
17 Odds ratios, chi-square, and Fisher's exact test for placental infection with <u>Ureaplasma</u> , given selected maternal characteristics	42
18 Significant odds ratio estimates for placental infection with <u>Ureaplasma urealyticum</u> by univariate logistic regression	45
19 Logistic regression models	46
20 Odds ratio estimates for placental infection with <u>Ureaplasma urealyticum</u> by multivariate logistic regression, Model I	48
21 Odds ratio estimates for placental infection with <u>Ureaplasma urealyticum</u> for various hypertension classifications using multivariate logistic regression, Models II - IV	50

LIST OF FIGURES

<u>Figure</u>	<u>Page</u>
1 Diagnosis and classification of diabetes mellitus	16
2 Study admission flow chart	30
3 Placental infection status with <u>Ureaplasma</u> <u>urealyticum</u> by complication classification	44
4 Placental infection status with <u>Ureaplasma</u> <u>urealyticum</u> by hypertensive classification	44
5 Odds ratios for placental infection with <u>Ureaplasma urealyticum</u> associated with diabetes only or hypertension only	49
6 Odds ratios for placental infection with <u>Ureaplasma urealyticum</u> by hypertensive classification	52
7 Odds ratios for placental infection with any bacteria associated with elevated blood pressure during pregnancy	53

CHAPTER 1

INTRODUCTION

Biology/Ecology of the Ureaplasmas

The ureaplasmas are spheroidally to coccobacillary shaped cell-wall-free organisms of the order mycoplasmatales, family mycoplasmataceae. Their size ranges from 100 to 850 nanometers, with an average of 330 nanometers. They are nonmotile and stain gram negatively, but are poorly visualized. The ureaplasmas have a genome of approximately 4.5×10^8 daltons, and G + C content in DNA of 27-30 mol percent. Their growth is optimized when the pH is at 6 and the temperature is 37°C. Ureaplasmas are microaerophilic and, on solid agar, produce colonies 15-60 μm , although there may not necessarily be growth on the surface of the medium. They all require sterol for growth and have the ability to reduce nicotinamide adenine dinucleotide oxidase in their cytoplasm. These organisms do not ferment carbohydrates and are sensitive to tetracycline, erythromycin, streptomycin, chloramphenicol, gentamicin, and kanamycin. They are differentiated from the genus Mycoplasma by their ability to hydrolyse urea.¹²⁵

Ureaplasmas were first isolated in 1954 from the urethra of men with urethritis and identified as "T-strain" mycoplasmas.¹¹² It wasn't until 1967 that the observations on urease activity¹¹³ and the requirement of urea for growth of these organisms,³⁴ which differentiated them from other mycoplasmas, was published. This characteristic was the basis for the eventual designation of Ureaplasma as a separate genus in 1974.¹¹⁵ Since the time of the first isolations, ureaplasmas have been isolated from a wide variety of host species. These include humans, non-human primates, mammals, and avian species. At this time, there are only two recognized species of ureaplasma: Ureaplasma urealyticum, which is found in humans, and U. diversum, which inhabits cattle. Isolates from other species have not yet been given species designations, pending

acquisition of an adequate number of isolates with which to conduct the necessary analyses and comparisons.

U. urealyticum and U. diversum have been isolated from the upper and lower portions of both the urogenital and respiratory tracts of their respective host species. Isolates have been made from one or more of these sites in other species of animals, but not from all four sites in any one species. This may simply be a reflection of how actively these organisms were sought in a given host. Overall, however, most isolations from all hosts species (18 total) combined have been made from the lower genital tract (14/18), followed by upper respiratory (10/18), lower respiratory (5/18), and upper urogenital (4/18) tracts.¹²⁶ U. urealyticum has also been isolated from placental and amniotic fluid cultures from pregnant women, areas viewed as an extension of the upper genital tract.^{8, 19, 21, 37, 41, 124}

Isolations from the products of both spontaneous^{20, 28, 65, 66, 101, 117} and induced abortions^{20, 101, 117} have been well documented. Isolations of U. urealyticum have also been made from the cerebral spinal fluid of infants,^{40, 111, 135} as well as synovial fluid,^{121, 131, 136} from abscess material in older patients,^{10, 121, 131} and from human blood.^{37, 42, 82}

There have been a wide variety of tests and typing schemes used to differentiate U. urealyticum isolates serologically. The original classifications were proposed by Black in 1973, and used the growth inhibition (GI) test to separate T-mycoplasmas into eight serogroups.⁶ These same typing groups were subsequently used for the basis of typing schemes employing indirect immunofluorescence, indirect hemagglutination, and polyacrylamide-gel electrophoretic (PAGE) tests,⁷ as well as an enzyme-linked immunosorbent assay (ELISA),^{15, 129} and an indirect immunoperoxidase (IP) test.⁹⁴ Subsequently, Lin and Kass expanded the groupings to 11 serotypes, using a complement-dependent mycoplasmacidal test.⁷³ Lin and Kass' classification retained the original eight serotype designations while adding three new, previously unrecognized groups.⁷³ Subsequently, Robertson and associates developed a different grouping system, again retaining Black's original eight groups. Robertson and Stempke added a ninth group, which was different from any of Lin et al.'s. new groups.¹⁰² Later, they added a 10th group. Then, by using a modified

etabolic inhibition test along with a colony epifluorescence test, they were able to combine their system with Lin's to produce a 14-group serotyping system.^{74,103} The 14-serotype scheme is the system generally used at this time, although some workers have suggested a 16-group system based on the mycoplasmacidal assay.^{62,72} Additionally, by using a combination of DNA homology, restriction endonuclease DNA digestion patterns, PAGE patterns, and sensitivity to manganese salts, these serogroups can be further separated into two major genomic clusters and one serogroup, which does not fit into either cluster.³

Association with Various Conditions/Diseases

Ureaplasma urealyticum is routinely isolated from normal, healthy individuals,^{32, 43, 54, 112} as well as from patients with a wide variety of medical problems. However, isolation from an individual with a given problem or illness does not necessarily mean that there is a causal association between U. urealyticum and the existence of the condition.

Ureaplasma Infection in the Upper and Lower Urogenital Tract

Studies consistently find an association between U. urealyticum and nongonococcal urethritis^{9, 16, 25, 33, 112} and Reiter's syndrome, a triad of diseases that includes urethritis, followed by conjunctivitis and arthritis.³³ U. urealyticum has also been isolated from the prostate glands of men suffering from chronic prostatitis;^{16, 17, 91} however, its ability to cause the condition has not been established. Likewise, the organisms have been isolated from the bladder of healthy individuals⁴³ and from the bladder^{5, 84} and kidney⁵ in cases of upper urinary tract diseases, such as pyelonephritis.⁵

U. urealyticum has been isolated from approximately equal proportions of healthy control patients and women suffering from pelvic inflammatory disease (PID).^{32, 75} It is possible that it causes disease in a small subset of women,⁵¹ and it has been suggested that U. urealyticum may act as a secondary or opportunistic invader under certain circumstances.^{122, 123}

Although there is no question that U. urealyticum can be isolated from both men and women suffering from involuntary infertility or reproductive failure, there is conflicting evidence as to whether there is a true association, causal or otherwise, between the organism and the disease process.^{23, 44, 45, 46, 55, 56, 65, 100, 120} Isolation of U. urealyticum has been found to be associated with a

reduction in sperm cell counts and an increase in sperm cell abnormalities of the male partner of infertile couples.³⁶ There is also good evidence that the organisms actually colonize specific portions of the sperm cell, and can be found in association with specific cell anomalies.³⁵

Ureaplasma and Pregnancy Outcomes

There have been numerous studies looking at the association between U. urealyticum and various pregnancy outcomes. The majority of studies have shown an association between Ureaplasma and spontaneous abortion,^{20, 31, 50, 65, 66, 101, 117, 120} although there are some conflicting data.⁴⁹ The association holds up when the spontaneous abortions are compared to therapeutic abortions (Table 1). Studies have also shown an association between chorioamnionitis and infant colonization with Ureaplasma⁹⁰ as well as with placental infection.^{31, 53, 67, 95, 96}

Table 1. Isolation rates (percent) of Ureaplasma urealyticum from the conceptus of spontaneous and induced abortions

	TYPE OF ABORTION		OR (CI ₉₅)	p
	Induced	Spontaneous		
Robertson et al. ^a	8.0	24.0	3.4 (2.0, 4.8)	<.001
Somplinsky et al. ^b	0.0	62.0	∞ (1.8, ∞)	.003
Caspi et al. ^c	3.7	32.1	11.8 (6.9, 16.6)	<.001

^a Robertson et al.¹⁰¹

^b Slompinsky et al.¹¹⁷

^c Caspi et al.²⁰

Ureaplasma Infection in Fetuses and Infants

Researchers looking at the relationship between cervical colonization and low birthweight infants have shown conflicting results. Studies in Mexican-American,⁴⁹ Navajo,⁴ and British women⁵⁰ failed to find an increased risk of low birthweight outcome with a positive ureaplasma cervical culture. However, several other studies have found an increased risk of reduced birthweight with cervical,^{12, 61} placental,^{31, 67} or infant nasal/throat^{12, 64} infection with U. urealyticum.

Maternal endocervical infection with ureaplasma has not been found to be associated with intrauterine growth retardation (IUGR).^{50, 93} When considering whether or not there is an

association between placental infection and IUGR, there are conflicting results.^{31, 67} The difficulty in comparing these results is that the criteria for IUGR differed from study to study.

Evidence of fetal bronchopneumonic infection with Ureaplasma has been documented as early as 19 weeks gestational age.^{28, 97, 106} Waites et al.¹³⁴ detailed three cases of persistent pulmonary hypertension in newborns in which the infants were infected with Ureaplasma, two of whom subsequently died. Other studies have shown an association between maternal and infant infection with Ureaplasma and the subsequent development of respiratory disease,^{98, 107, 118} but not with prolonged oxygen dependence.¹⁰⁷ In a series of 290 perinatal deaths, Ureaplasma was the only organism isolated from the lungs of 24 infant; of these, 22 were stillbirths, and 23 were diagnosed as having congenital pneumonia.¹²⁴ It has been shown that, among low birthweight infants infected with Ureaplasma, the lower the weight class, the higher the risk for development of chronic lung disease (Table 2).^{22, 109, 133}

Although individual cases of meningitis due to Ureaplasma infection have been verified,⁴⁰ prospective studies have given conflicting results as to the association between Ureaplasma and meningitis.^{71, 111, 135}

Ureaplasma has also been found to be associated with perinatal death. In a study by Quinn et al., Ureaplasma was isolated from 56.5% of infants with no known morphologic or anatomic cause of death, and only 10% of the normal living controls.⁹⁵

Serovar Associations with Various Conditions/Diseases

A listing of the serotypes associated with various conditions for which studies have been done is compiled in Table 3. Due to various typing methods and schemes used, it is difficult to compare the results of different studies. Several studies failed to find any difference in the distribution of the different serotypes in normal men,⁹² or normal infants and mothers when tested for a serologic response.⁹⁹ However, several studies have found an increase in certain serotypes in sexually active men^{114, 119, 132} and in women who experienced normal pregnancies.⁸⁷

Although the study by Piot⁹² did not find an association between any particular serotype of Ureaplasma and nongonococcal urethritis (NGU), other studies have found an association.^{114, 119}

Associations have also been found in cases of chronic prostatitis, and renal stones.¹¹⁴ Another study found an increase in the proportion of various serotypes in cases of atrophic pyelonephritis, glomerulonephritis, and recurrent urinary tract infection.⁵²

Table 2. Development of chronic lung disease (CLD) in low birthweight infants by Ureaplasma status

Study	Birthweight Criteria	Percent CLD		p
		Uu +	Uu -	
Sánchez and Regan ^a	≤2000 g	30	8	≤.05
Wang et al. ^b	≤1250 g	72	32	≤.0001
Cassell et al. ^c	≤1000 g	82	41	≤.02

^a Sánchez and Regan,¹⁰⁹ CLD measured at 30 days of age

^b Wang et al.,¹³³ CLD measured at 28 days of age

^c Cassell et al.,²² CLD measured at 28 days of age

In studies of infertile women,^{24,25} increases of certain serotypes were found that were different from the pattern found in proven fertile women.²⁴ In serologic⁹⁹ and culture¹⁰¹ studies of women with a history of pregnancy loss, there were significant increases in reactions against as many as five different serotypes of Ureaplasma. Among infants with respiratory disease, there is evidence for an association between disease with death and two serotypes (serotypes 4 and 8), and a third serotype was associated with disease and survival (serotype 5).⁹⁸

Risk Factors for Infection

Infections in Infants

It has been noted that a greater proportion of female infants are infected than males at birth, and that an infant born vaginally is at higher risk of being infected than one born via cesarean section.⁷⁸ In a study population with six sets of twins delivered vaginally, 66.6% (4/6) of the sets had an infant infected with either Ureaplasma or Mycoplasma, although the authors did not differentiate between the two in this part of the study. In each case, only the first-born infant was infected.⁶⁴ Although the authors did not state why this should be the case, it would seem

Table 3. Serotypes of *U. urealyticum* found in association with various conditions

Condition	Serotype											
Normal												
male urethra	2	3	4				8	9	10	11		13 14
female endocervix		3			6							
placenta		3			6					11		13 14
conceptus (therapeutic abortion)		3			6					11		13 14
Nongonococcal urethritis (NGU)			3 4							11		13 14
Chronic prostatitis			4									
Recurrent urinary tract infection (RUTI)	1	3			6							
Atrophic pyelonephritis	1	3			6							
Glomerulonephritis	1				6							
Renal stones	1											
Infertility	1	3	4	5	6		8					
Spontaneous abortion		3	4		6		8			11		13 14
Premature rupture of membranes (PROM)		3			6							
Stillbirth		3										
Respiratory disease												
all cases				4		7	8					
with death				4			8					
survived					5							

reasonable that during the process of the first infant passing through the birth canal, it became infected and reduced the population of the organism in the canal to below infective levels.

Additionally, there is a trend for increased risk of infection with decreased birth weight. If this risk is assessed using as the groups infants <2500 grams and those \geq 2500 grams, those in the former group are significantly more likely to be infected at birth.⁶⁴ Whether the low birthweight is due to the infection or is indicative of an underlying condition in the pregnancy which, in turn, predisposes the infant to becoming infected has not yet been determined.

Infections in Children

Using urinary culture isolation as the indicator of infection status,³⁸ an age trend in proportion infected was seen in normal children. There was an increase in proportion infected with increasing age, that started earlier in females and exhibited a quicker increase to a higher level. The increasing rate of infection with age may be due to the effect of two separate factors, the sexual activity of the individual and/or the hormonal status of the female.

Sexual Activity and Infection in Adults

It has been effectively demonstrated that the degree of sexual activity and particular sexual practices are major factors in determining the risk of infection in both the male⁸³ and the female (Table 4).^{79, 80} It has been shown that even having genital contact without actual intercourse increases the risk of infection for the individual. Additionally, the risk of infection increases with the number of different sexual partners. Not surprisingly, use of barrier contraceptives reduces the risk of infection, but does not eliminate it. When McCormack et al.⁷⁹ compared sexually active and inactive women in a predominately white population (98.9%), they found an infection rate of only 5.6% in the inactive group and a rate of 49.1% in the active group. The mean age of the study population was 20.6 years. A subsequent study by McCormack and co-workers, using a more racially diversified group of women, found infection rates of 18.6% and 62.1% in the inactive and active groups, respectively.⁸⁰ However, they did not detail the age composition of this study group. Iwasaka et al.⁵⁷ also compared sexually inactive and active women in Japan and found infection rates of 22.4% for inactive and 66.7% for active women. However, the active group was almost 11

Table 4. Percent Ureaplasma infection in men and women as a function of sexual activity and contraceptive practices

Activity	Male ^a			Female ^b			
	Overall	Barrier Yes	No	Overall	Overall	Barrier Yes	No
No genital contact	0.0	-	-	5.6	18.6	-	-
Genital apposition without penetration	6.7	-	-	26.7	-	-	-
Intercourse							
Any	35.9	14.3	42.9	49.1	62.1	50.0	66.6
1 partner	18.8	10.0	22.7	37.5	38.8	38.2	39.1
2 partners	26.1	-	35.3	54.5	54.4	47.4	57.1
≥ 3 partners	44.8	21.1	51.5	75.0	76.4	57.4	83.1

^a urinary tract

^b vaginal tract

years older than the inactive group (32.9 vs. 22.4 years mean age). Among pregnant women, the infection rates ranged from a low of 54% to a high of 90% in different populations (Table 5).^{11, 48, 49, 57, 70, 100}

Hormonal Influence on Infection Rates in Females

In looking at the influence of hormones on infection rates in women, Iwasaka et al.⁵⁷ found a vaginal colonization rate of 48% in newborn females, which dropped to 28.6% at 30 days of age, and to 4.8% at a mean age of 5.8 years. In another study,⁴⁷ conducted on a population of predominantly black girls between the ages of 2 months and 15 years, 27% of those between the ages of 2 months and 2 years, 22% of those between 3 and 10 years, and 40% of those between 11 and 15 years of age were positive. Forty percent of the girls in the oldest group were post-menarcheal. Unfortunately, the authors did not evaluate differences in the pre- and post-menarcheal girls in this group nor compare those who were sexually active with those who were not in order to differentiate between the effects of hormonal changes and sexual activity.

Table 5. Endocervical infection rates in pregnant women of various racial groups

<u>Study group</u>	<u>Country</u>	<u>Rate (%)</u>
American Indian ^a	US	81.2
Black ^b	US	90.0
Caucasian ^c	France	54.0
Caucasian/Hispanic ^a	US	72.5
Japanese ^d	Japan	77.9
Unspecified ^e	US	60.0
Unspecified ^f	US	71.1

^a Harrison⁴⁹

^b Hardy et al.⁴⁸

^c Liepmann et al.⁷⁰

^d Iwasaka et al.⁵⁷

^e Rehewy et al.¹⁰⁰

^f Braun et al.¹¹

When Iwasaka et al.⁵⁷ evaluated pregnant women, they found an infection rate of 77.9% (mean age of 28.8). They then compared the rates in pregnancies delivering at <35 weeks (mean age 28.4) and >36 weeks (mean age 29.2), and found rates of 70% and 82%, respectively. By 7 days postpartum, the infection rate had dropped to 67.6%, and by 35 days, the rate had dropped still further to 23.9%, approximately the same level found in the sexually inactive group. Rehewy et al.¹⁰⁰ compared rates of infection between sexually active and pregnant women ages 20 to 42, and found that 42.9% of the sexually active women were infected with Ureaplasma, whereas 60% of the pregnant women were positive.

One group of researchers found an increased prevalence of Ureaplasma infections in women who used oral contraceptives, but due to their study design, they could not explore the question as to whether hormonal changes or sexual activity was the contributing factor.⁸¹

Post-menopausal women were also evaluated. Those with an intact cervix had an infection rate of 35.7%, and those without a cervix had a rate of only 10%. The overall infection rate of this group of women was 25%. The ages of the two groups were comparable (61.9 and 62.0 years); unfortunately, the authors did not determine the sexual activity of these women.⁵⁷

Other Factors

Savige et al.¹¹⁰ found that an increased proportion of pre-eclamptic women demonstrated bladder urine infected with Ureaplasma when compared to normal pregnant women (20% vs. 7%, $p = .01$). These researchers also found that the organisms were present in higher numbers in the pre-eclamptic women. On the other hand, Kundsinn et al.⁶⁷ found a negative association between placental colonization and maternal diabetes or pre-eclampsia. The authors did not state whether the diabetes was pre-existing or gestational, or what level of control was achieved in these women.

Diabetes

Insulin-dependent diabetes mellitus (IDDM, or Type I) is a metabolic disorder characterized by the inability to oxidize carbohydrates, due primarily to destruction of β -cells in the pancreas, resulting in the loss of insulin production. Consequences of this loss are hyperglycemia, leading to

glycosuria and polyuria. Additionally, aberrations in the process of breaking down fats may lead to acidosis and ketosis, which may eventually cause coma and death.

The diagnostic criteria for IDDM in non-pregnant adults are any of the following:⁸⁹

- A. The presence of the classic symptoms of diabetes, i.e., polyuria, polydipsia, ketonuria, and rapid weight loss in conjunction with a gross and unequivocal elevation of plasma glucose.
- B. Elevated fasting glucose concentration on more than one occasion, as measured by:

venous plasma	≥ 140 mg/dl
venous whole blood	≥ 120 mg/dl
capillary whole blood	≥ 120 mg/dl.

- C. If the fasting glucose concentration does not exceed the criteria in section B, but there is a sustained increase in the oral glucose tolerance test (OGTT) concentrations at both 2 hours and at some other 30-minute sampling point between administration of a 75-gram glucose dose and the 2-hour sample, as measured by:

venous plasma	≥ 200 mg/dl
venous whole blood	≥ 180 mg/dl
capillary whole blood	≥ 200 mg/dl.(page 1049)

The diagnostic criteria for IDDM in children are either one of the following:⁸⁹

- A. Presence of the classic symptoms of diabetes, as in section A for adults, along with a random plasma glucose concentration > 200 mg/dl.
- B. If the child is asymptomatic, then both an elevated fasting plasma glucose concentration and a sustained glucose concentration during the OGTT on more than one occasion using the same criteria as in section C, above, using a modified dose of oral glucose (1.75 g/kg ideal body weight up to 75 g), concentrations measured by:

Fasting value:

venous plasma	≥ 140 mg/dl
venous whole blood	≥ 120 mg/dl
capillary whole blood	≥ 120 mg/dl.

2 hour OGTT values:

venous plasma	≥ 200 mg/dl
venous whole blood	≥ 180 mg/dl
capillary whole blood	≥ 200 mg/dl.(page 1049)

Non-insulin-dependent diabetes mellitus (NIDDM, or Type II) is a form of diabetes that usually, but not exclusively, has its onset after the age of 40. Sixty to 90% of all cases of NIDDM are obese. NIDDM diabetics do not require the use of insulin to control their illness, although it

may be used to correct some conditions associated with the disease, and they are not prone to the development of ketosis. The NIDDM diabetic may produce serum levels of insulin that are elevated, normal, or low. In the obese subclass of patients, the control of their weight may be enough to improve their glucose tolerance. NIDDM is diagnosed based on a fasting plasma glucose level ≥ 140 mg/dl, without the other signs and symptoms of diabetes associated with IDDM (ketosis, etc.).⁸⁹ The secondary complications associated with IDDM, such as hypertension, retinopathy, and nephropathy, are also seen in individuals with NIDDM.¹³⁸

Gestational diabetes mellitus (GDM) is a carbohydrate intolerance that is first diagnosed, or has its onset, during pregnancy. This intolerance usually resolves after the completion of the pregnancy. It may be controlled either with diet or insulin therapy. The criteria for diagnosis is a 100-gram oral glucose tolerance test during a pregnancy that yields 2 or more glucose concentrations equal to or greater than the following:⁸⁹

A. Venous plasma

Fasting:	105 mg/dl
1 hour post ingestion	190 mg/dl
2 hour post ingestion	165 mg/dl
3 hour post ingestion	145 mg/dl.

B. Venous or capillary whole blood

Fasting:	90 mg/dl
1 hour post ingestion	170 mg/dl
2 hour post ingestion	145 mg/dl
3 hour post ingestion	125 mg/dl. (page 1050)

Diabetes during pregnancy is classified based on time or age of onset and secondary complications present.¹³⁷ The classifications routinely used are listed in Table 6. The general criteria for the diagnosis and classification of DM are illustrated in Figure 1.

Hypertension

The diagnosis of chronic hypertension (CHT) in adults is confirmed when the average of two or more diastolic blood pressure readings is 90 mmHg or higher on at least two subsequent visits, or when the average of two or more systolic blood pressure readings is higher than 140 mmHg on two or more subsequent visits.⁵⁸

Table 6. White¹³⁷ classification of diabetes in pregnant women

CLASS	CRITERION
Class A	
A ₁	Glycosuria with a positive OGTT insulinopenia
A ₂	Abnormal OGTT with hyperinsulinism
A ₃	Obesity with an abnormal OGTT and insulinopenia
Class B	Maturity onset (age over 20), duration < 10 years, no vascular lesions
Class C	
C ₁	Onset age 10-19 years
C ₂	Duration of 10-19 years
Class D	
D ₁	Onset < 10 years of age
D ₂	Duration > 20 years
D ₃	Benign retinopathy
D ₄	Calcified leg vessels
D ₅	Hypertension
Class E	Calcification of pelvic arteries
Class F	Nephropathy
Class G	Many failures
Class H	Cardiopathy
Class R	Proliferating retinopathy
Class T	Renal transplant

Gestational, or pregnancy induced hypertension (PIH) is defined as either a single measurement of a diastolic blood pressure ≥ 110 mmHg or two consecutive measurements of diastolic blood pressure of 90 mmHg, 4 or more hours apart.²⁶ Pre-eclampsia is defined as proteinuria in addition to either CHT or PIH. Proteinuria can be diagnosed either by one 24-hour urine collection, with total protein excretion of ≥ 300 mg per 24 hours, or by two "clean-catch-midstream" or catheter specimens collected ≥ 4 hours apart, with 1 g/l of albumin or 2+ or more on a reagent strip or sulfosalicylic acid "cold" test, or 0.3 g/l of albumin or 1+ on a reagent strip when the specific gravity of the urine is < 1.030 and the pH is < 8.0 .²⁶ Eclampsia has the same

diagnostic criteria as pre-eclampsia, with the addition of the occurrence of convulsions during pregnancy or labor, or up to 7 days postpartum, which are not caused by epilepsy or any other preexisting convulsive disorder.²⁶




Figure 1. Diagnosis and classification of diabetes mellitus.

CHAPTER 2

RATIONALE

Diabetes

It has been shown in a retrospective study that diabetic women are at increased risk of endometritis and wound infection after a Cesarean section delivery.²⁷ This increase has been seen in both normal and diabetic pregnancies as the overall risk of subsequent infection after delivery increased (Table 7). High risk was defined as either rupture of membranes or labor prior to

Table 7. Infection rates (percent) of low- and high-risk pregnancies of diabetic and non-diabetic women

	Low risk	High risk	p
Non-diabetic	1.8	6.0	NS
Diabetic	9.0	25.0	.067
p	.042	.032	< .001 ^a

^a High-risk diabetic compared against low-risk non-diabetic pregnancy

Cesarean section, and low risk as not having experienced either. Diabetics were at a significantly higher risk of infection in both categories of low and high risk when compared to non-diabetics in the same classifications. Pregnant diabetic patients have also been shown to be at increased risk for infection with Group B Streptococcus [RR 2.04, CI (level not specified) 1.03, 3.79; p <0.05]. The increase in risk was essentially the same whether the diabetes was gestational or pre-existing.⁷⁶ Among the general non-pregnant population of individuals infected with Lancefield Group C or G Streptococci, there was an association with DM as a predisposing condition.^{108, 130}

Animal studies in rats with chemically induced diabetes have demonstrated changes in protein metabolism in both the placenta and fetus.^{18, 104} In the placenta, the rates of protein

synthesis were comparable in both normal and diabetic animals throughout the pregnancy. However, late in the pregnancy, there was a dramatic decrease in the degradative rate of protein in the placentas of the diabetic animals, which, in the face of unaltered synthesis rates, led to the development of enlarged placentas.¹⁰⁴ In the fetus, the rate of protein synthesis was lower in the fetuses of diabetic rats than that of normal animals. Additionally, the rate of protein degradation in the fetuses of the compromised animals was increased, which led to the production of smaller fetuses.¹⁸ A similar mechanism may also play a role in the growth-impaired human fetus. An alteration in the balance between the synthesis and degradation of protein could lead to an excess of urea, one of the byproducts of protein metabolism, providing an increase in availability of a substrate for Ureaplasma growth.

Hypertension

It has been shown that, during pregnancy, there is a significant shift to the right of the oxyhemoglobin dissociation curve (P_{50}) during each trimester. The shift increases with gestational age, which makes more oxygen available to the fetus as the pregnancy progresses. However, in pre-eclamptic women at term, the P_{50} curve is shifted to the left of that of a normal non-pregnant woman, which would lead to reduced availability of oxygen for both mother and fetus, and significantly so, when compared to the expected value of a normal pregnant woman ($p < .001$).⁶⁰ In a subsequent study, it was found that the carboxyhemoglobin levels were significantly increased in pre-eclamptic women as compared to normal pregnant women (2.8% vs 0.7%, $p < 0.001$), reducing the availability of oxygen. This study reconfirmed the lower P_{50} values found in the earlier study, and proposed the increased levels of carboxyhemoglobin as the mechanism for the lowered P_{50} curve.⁵⁹ Reduction of available oxygen in the maternal and fetal environment may be advantageous for the growth of *U. urealyticum*, a microaerophilic organism.

A study by Musci and coworkers⁸⁶ has demonstrated mitogenic activity in the sera of pre-eclamptic women, indicating endothelial cell injury, and Rogers et al.¹⁰⁵ demonstrated an endothelial cell cytotoxic serum factor in preeclamptic women. This injury can cause the secretion of mitogens and vasoactive factors, due to the production of peptide growth factors by the endothelial cells or

by the release of stored products by activated platelets. These components, or their degradative products, could act as growth promoters or substrates for Ureaplasma. Cellular injury could also compromise the integrity of the endothelial lining of the blood vessels, allowing easier passage of any infectious agent into the blood and through the placental barrier.

Hypotheses

Two hypotheses were tested in this study. Either maternal diabetes, or maternal hypertension, by virtue of physiologic changes in the maternal-uteroplacental environment due to either of these conditions, expose the placenta to an increased risk of infection with Ureaplasma urealyticum. Secondly, hypertension will be further subdivided into chronic and pregnancy-induced (acute) hypertension, to see if either type has a greater effect on the risk of infection.

CHAPTER 3

METHODS

Study Design

A cross-sectional study of Cesarean section births without rupture of the fetal membrane was conducted. This sampling controlled for the possibility of infection due to contamination by passage through the birth canal, or by migration of the organism back to the placenta after the rupture of the fetal membranes. The study population consisted of all women who had a Cesarean section performed at the University of Alabama at Birmingham Medical Centers between October 26, 1987, and July 31, 1990. Only those women who delivered an infant with an intact fetal membrane during this time were enrolled in the study. If a woman met the criteria for enrollment into the study more than once during the study period, only the first delivery was included in the analysis.

The specific aim of this study was to evaluate if there is an increased prevalence of placental infection with Ureaplasma urealyticum among pregnant women with the predisposing conditions of maternal diabetes or hypertension. The diabetic conditions considered in this study are insulin dependent diabetes mellitus (IDDM), non-insulin independent diabetes mellitus (NIDDM) and gestational diabetes (GDM). These conditions were considered as a single group. Hypertensive conditions included in the study were both chronic (CHT) and acute, also called pregnancy induced (PIH), hypertension. The conditions were considered individually by subgroups of the major hypertensive complications (pre-existing or pregnancy-induced, superimposed), as well as the pooled groups (all diabetes or all hypertension).

Power Calculations

Prior to closing the data collection period, power estimates were developed, based on the population characteristics (Table 8) and rate of enrollment in December of 1989. If the rate of enrollment per month remained constant, and the proportions of complications and the incidence of infections remained the same, there would have been an estimated 573 births enrolled by the end of July 1990, the originally anticipated ending date for this study. The estimated numbers for the various subgroups of this population are listed in Table 9. Using the formula:

Power = $1 - \Phi(A)$, for a binary outcome measurement using a chi-square approximation with non-uniform allocation, where:

$\Phi(A)$ = proportion of area of a $N(0,1)$ distribution that is to the left of a point A, and

$$A = \frac{Z_{\alpha} \sqrt{PQ/n_c + PQ/n_n - |P_c - P_n|}}{\sqrt{P_c Q_c/n_c + P_n Q_n/n_n}}$$

with:

- Z_{α} = Z value for error level
- P = proportion of population infected
- Q = proportion of population not infected
- P_n = proportion of comparison population infected
- P_c = proportion of population with complication infected (hypothesized)
- n_n = number in comparison group
- n_c = number in complication group,

the proportions in Table 8, and the n's from Table 9, power estimations for a 1-tailed test were produced with a hypothesized 2-fold increase in infection rate for the complication groups for the estimated population size at the closing date for this study (Table 10). Because the biological changes would be expected to be the same for all types of diabetes, although they would be acting for a shorter duration in gestational diabetes, it seemed both reasonable and appropriate to pool these conditions.

Accepting an error rate of .10, all classes of complications would have a power >.80. If a more conservative error rate of .05 is used, then the power for the chronic hypertension group drops to <.80.

Power estimates were also calculated for several different odds ratios (1.5, 2.0, 2.5, and 3.0), using the one-sided test at two error levels. The curves for the differing ORs for the different

Table 8. Characteristics of the mothers and infants enrolled into the study population through December 31, 1989

		Number	Percent
<u>Mother</u>	Total	433	
	Infected	50 ^a	11.5
	Confirmed diabetes (pre-existing and gestational)	61	14.1
	Chronic hypertension	45	10.4
	Pregnancy-induced hypertension	79	18.2
	Hypertensive illness	117	27.0
<u>Placentas</u>	Total	455	
	Infected	55	12.1
	Sets of twins	23	
	At least one placenta infected	9	39.1
	Both placentas infected	5	21.7
	Only one infant with intact membrane	1	4.4

^a Number of women yielding at least one infected placenta

^b Percent of infected sets (5/9)

complication groups are presented in Appendix 1. As can be seen from the curves, should the OR actually be ≥ 2.5 , there would be adequate power to detect this. However, if the true OR for any group should be 1.5, all of the groups would have power $< .80$.

Data Collection

Infection status

Placentas were collected aseptically at delivery, and laboratory personnel were notified. The placentas were refrigerated until processing, usually within one hour of birth. Using aseptic

Table 9. Estimated study size and characteristics

	n_c^a	n_n^b
All diabetics	81	492
Chronic hypertension (CHT)	60	513
Pregnancy-induced hypertension (PIH)	137	436
CHT or PIH	155	418
Total infected	67	506

^a = Number in population with condition

^b = Number in population without the condition

Table 10. Power calculations for estimated study population (N=573), with a 2-fold increase in the proportion infected

Group	Number		Power	
	n_c^a	n_n^b	$\alpha = .10$	$\alpha = .05$
Diabetes (all classes)	81	492	.91	.85
Chronic hypertension	60	513	.84	.76
Pregnancy-induced hypertension	137	436	.97	.94
Either hypertensive complication	155	418	.97	.95

^a = Number with the complication of interest

^b = Number without the complication of interest

technique, the chorioamniotic membrane was removed from the placenta with a sterile blade, and three to five sets of parallel incisions were made on the fetal side of the placenta. For each set of incisions, the surface layer of the placenta between the two incisions of the set was peeled back, and three swabs were swabbed between the chorion and amnion of one of the incisions. One swab was used to make a slide for gram staining, and the remaining two were used to inoculate 1.5-2.0 ml of

2-sucrose phosphate (2SP). The swabs were expressed and discarded, and the resulting suspension was used to inoculate culture broths and plates for the isolation of Ureaplasma, Mycoplasma, other aerobic and anaerobic bacteria, and fungi. From the second incision of each set, at least 1 cm² was teased out into a sterile petri dish and thoroughly minced in 1.8 mls of 2SP, and the resulting suspension was used to inoculate the media. For each inoculum, approximately 0.5 ml was drawn up into a 10-cc syringe, and 0.1 ml was inoculated into one tube each of Chopped Meat Carbohydrate Media (CMC), Brain Heart Infusion Broth (BHI), Tricosele, and McCoy cell line cell culture. Dilutions of the original inoculum were made by adding 0.1 ml of the original suspension to 0.9 ml each of 10B¹¹⁴ with Cefobid and SP4^{127, 128} with Cefobid, and then making serial 10-fold dilutions out through the 10⁻⁵ dilution.

Using an 0.01-ml calibrated loop, the following agar plates were inoculated with the original 2SP suspensions and streaked for isolation: two plates of Campylobacter medium (Campys), and one each of chocolate agar, sabaroud dextrose agar (SAB), human blood-tween 80 agar (HBT), and pre-reduced Columbia blood agar (CBA). A plate of A8¹²⁸ agar was divided into sections, and 0.02 ml of the original 2SP inoculum and the 10B dilutions were spot-inoculated onto the plate for colony counts. Incubation conditions for the various media and the organisms isolated from them are listed in Table 11.

If growth was observed in the BHI or CMC, a gram stain was made, and those media were inoculated onto appropriate media for isolation and identification of the organisms present. BHI was inoculated onto blood agar (BA) and eosin-methylene blue agar (EMB), which were incubated at 37°C for 2 days under aerobic conditions, and onto chocolate agar, which was handled as shown in Table 11. CMC was inoculated on BA, chocolate agar, and CBA, and incubated as previously noted.

Ureaplasma and Mycoplasma were identified by their growth in the appropriate medium and morphologic characteristics on A8 medium. Aerobic bacteria other than Ureaplasma were identified using the API strip systems for gram positive and gram negative organisms, and the anaerobic organisms were identified using gas liquid chromatography (GLC) and additional sugar

Table 11. Incubation conditions for culture media and organisms

Medium	Form	Atmosphere	Temperature (°C)	Days held	Organism
BHI	Broth	Aerobic	37	7	Aerobic bacteria other than <u>Ureaplasma</u>
10B	Broth	Aerobic	37	14	<u>Ureaplasma</u>
SP4	Broth	Aerobic	37	60	<u>Mycoplasma</u>
Trichosel	Broth	Aerobic	37	5	<u>Tricomonas</u>
SAB	Agar	Aerobic	37	30	Fungi
A8	Agar	5% CO ₂	37	14	<u>Ureaplasma</u> , <u>Mycoplasma</u>
HBT	Agar	5-10% CO ₂	37	2	<u>Gardenerella vaginalis</u>
Campys	Agar	5-10% CO ₂	37, 42	2	<u>Champylobacter</u>
Chocholate	Agar	5-10% CO ₂	37	2	Bacteria other than <u>Ureaplasma</u>
Chlamydia	TC*	4.5% CO ₂	37	2	<u>Chlamydia</u>
CMC	Broth	Anaerobic	37	5	Anaerobic bacteria
CBA	Agar	Anaerobic	37	5	Anaerobic bacteria

* TC = Tissue culture, cyclohexamide treated McCoy cell mono-layer.

utilization tests, as needed. Chlamydia were identified using fluorescein-conjugated monoclonal antibodies and immunofluorescent microscopy to visualize inclusion bodies in the McCoy cells. Trichomonas was identified by examining a wet prep after 2 and 5 days of incubation, at 450X magnification using bright field illumination.

Maternal Characteristics

Maternal characteristics required for analysis were obtained from the Obstetrical Automated Record System (OBAR) and the University Hospital's medical records. OBAR is an integrated, computerized medical record system, which draws on obstetrical patients from the University and Cooper Green Hospitals, and the Jefferson County Health Department Clinics. Information for the OBAR system on the mothers and fetuses was collected during prenatal visits, and maternal and infant information was collected at delivery on standardized forms (Appendix 2). Prenatal clinic records are validated by a monthly medical records audit, whereby a random sample of the previous month's records are reviewed to compare against the data actually entered into the OBAR database. The discharge summary for each birth undergoes a chief resident's review comparing the summary against the actual records.

In this study, pre-existing diabetes was defined as an established history of diabetes, either by abnormal blood glucose levels, as described previously, or a documented history of treatment with either anti-diabetic drugs or diet, in a non-pregnant individual. A history of previous incidence of gestational diabetes that resolved after delivery was not counted as a current diabetic. Gestational diabetes was defined as diagnosis made during the current pregnancy, in a woman with no history of diabetes during non-pregnant periods of life. Diagnostic criteria included either a documented 3-hour oral glucose tolerance test with a minimum of two abnormal readings, multiple fasting blood glucose levels ≥ 140 mg/dl, or documented use of any anti-diabetic treatment initiated during the pregnancy.

For this study, a woman was classified as a chronic hypertensive if she had documented evidence of hypertension during the non-pregnant periods of her life. Evidence consisted of either the appropriate increase in blood pressure, as previously described, or documented treatment with

any antihypertensive agent. An increase during the first trimester was considered to be a case of chronic hypertension. Pregnancy-induced (acute) hypertension was verified by a documented increase of blood pressure occurring after the beginning of the second trimester. The minimum readings required were either two diastolic readings ≥ 90 mmHg or two systolic readings ≥ 140 mmHg, or one of each, separated by at least 6 hours, or a single diastolic reading ≥ 110 mmHg. A woman who experienced acute hypertension during a previous pregnancy that resolved with no further signs or symptoms of hypertension during the intervening time or the current pregnancy was not classified as a hypertensive for purposes of this study.

Validation of Complication Status

The complication status of the women in this study was validated by a medical record review. All records indicating the presence of one of the complications of interest were requested from the University Hospital Medical Records Division and reviewed, using the previously detailed criteria for determination of complication status. Any record with no indication of a complication but with missing data was also reviewed. Finally, a 20% random sample of the remaining records with all information present and without any indication of complications was also reviewed.

Data Analysis

The independent variables considered were: 1) any diabetes, 2) pre-existing hypertension, and 3) gestational hypertension. Pre-existing diabetes and gestational diabetes were evaluated as a single group. The hypertensive classes of conditions were evaluated both individually and as a group.

The outcome variable was whether or not the mother experienced a pregnancy in which one or more placentas were infected with Ureaplasma urealyticum. Infection status was ascertained by culturing each placenta. Culture material consisted of both swabs and tissue inoculated on solid agar and in liquid media. A placenta was considered to be positive for Ureaplasma if at least one of these samples produced growth of the organism. The individuals who determined the culture status of the placentas were blinded to the complication status of the women tested.

Confounding variables controlled for in the analysis included the following: maternal age, race, marital status, socioeconomic status (measured by level of education and insurance coverage), smoking status, presence of placental infection with any other organisms, presence or absence of labor and the duration of labor when present, pre-term delivery both during the present and previous deliveries, and primigravida status.

Analysis of the maternal data set consisted of comparing the proportion with the target condition in the women with placentas infected with Ureaplasma against women whose placentas had no evidence of placental infection with Ureaplasma.

Chi-square analysis of the 2 X 2 contingency tables was conducted on both the crude data and the data stratified by the appropriate subclasses of the complications. When appropriate, due to small numbers, Fisher's exact test was used, rather than the chi-square.

Logistic regression analysis was used to determine the odds ratio (OR) and confidence intervals for the risk of a mother producing an infected placenta given the mother's complication status during her pregnancy. Use of this type of analysis allowed for building a model that took into consideration the known risk factors for infection with Ureaplasma. Various models have been used to determine risk factors for infection with Ureaplasma in different populations.^{4, 49, 53, 67, 80, 81, 95} Variables that have been associated with infection and were included in the initial model are as follows: race,^{67, 80} maternal age,^{4, 53, 67} marital status,^{67, 81} smoking,^{67, 80} concurrent bacterial infection of the placenta^{4, 49} duration of labor,^{4, 53} and SES as determined by years of education.⁵³ As we had access to information concerning insurance coverage, we also used this as a measure of SES. For all analyses, a p-value <0.05 was considered a significant result, p-values $\geq 0.05 - 0.10$ were given as their actual value, and p-values >0.10 were considered not significant and presented as NS. Because the hypothesis was that there would be an increased risk of infection with Ureaplasma in the complication groups, chi-square and Fisher's exact tests were 1-tailed. Multivariate logistic regression probabilities were reported as 2-tailed: any difference from the null expectation of no difference.


CHAPTER 4

RESULTS

Comparison of Study Population Groups

Between October 26, 1987 and December 31, 1990, a total of 8,222 deliveries were recorded in the OBAR system for the University Hospital. The type of delivery was classified as either vaginal (VAG), Cesarean section with ruptured membranes (CRM), or Cesarean section with intact fetal membranes (CIM). Of the 8,222 deliveries, 256 were not classified as to the type of delivery experienced. The characterization of the types of deliveries is shown in Figure 2. Of the 815 Cesarean section deliveries, 646 were enrolled into the study, and 169 were missed due to duty clerks and nurses not informing the study nurse on call that a delivery had taken place so that the specimens could be processed. One woman enrolled who delivered twins was excluded when it was determined that the Cesarean section was for the second infant following a vaginal delivery of the first infant.

Demographic characteristics of the different delivery groups are listed in Table 12. The three delivery groups differed significantly from each other (Table 12). The racial composition of the VAG group was comparable to that of the CRM group, with the proportion of blacks being almost 2-fold greater than whites in both groups (Table 13). However, the proportions of blacks and whites were approximately equal in the CIM group, which was significantly different from either of the other two groups (Tables 14 and 15). The marital status characteristics did not differ significantly between the two Cesarean groups, but each group did differ from the vaginal delivery group. This difference was due entirely to differences between the black women in each group ($p \leq 0.05$ for VAG versus CRM and VAG versus CIM). Mean maternal age at delivery differed significantly among all three groups, with the vaginal delivery group being the youngest,



* = percent of total delivery population during study period.

Figure 2. Study admission flow chart.

Table 12. Population characterization for University Hospital deliveries between October 26, 1987 and December 31, 1990

		TYPE OF DELIVERY		
		Vaginal	Cesarean ruptured membrane	Cesarean intact membrane enrolled
		(n = 5,893)	(n = 1,258)	(n = 645)
% Race	White	34.6	38.1	47.4
	Black	64.9	61.5	52.2
	Other	0.5	0.4	0.4 ***
% Marital status	Single	54.1	48.1	40.8
	Married	37.4	44.8	50.4
	Divorced	4.2	3.5	4.2
	Separated	4.1	3.3	4.4
	Widowed	0.3	0.2	0.2 ***
Mean maternal age		24.3	25.6	26.3 ***
Mean years of education		11.8	12.1	12.1 ***
% w/ Medical coverage	Insured	11.9	30.5	32.0
	Indigent	88.1	69.5	68.0 ***
% Previous C-section		2.3	6.7	12.3 ***
Mean hours of labor		15.7	20.6	11.3 ***
Mean birth weight (gms)		3041.9	2796.1	2662.3 ***
Mean gestational age (weeks)		37.7	36.5	36.1 ***
% Pre-term delivery		21.3	37.4	44.3 ***
% Post-term delivery		0.5	1.0	0.9 *
% Multiple births		8.7	13.2	5.6 ***
% Smoked during pregnancy		19.3	15.8	25.6 ***
% Alcohol use during pregnancy		10.9	7.7	10.1 *
% Any history of drug use		8.3	6.1	3.9 **
% Anomalies		1.8	5.1	6.7 ***
% History of venereal disease		1.2	1.4	14.8 ***
% Maternal infection during pregnancy		8.3	7.9	6.5

Table 12. - Continued.

	TYPE OF DELIVERY		
	Vaginal (n = 5,893)	Cesarean ruptured membrane (n = 1,258)	Cesarean intact membrane enrolled (n = 645)
% Urinary tract infection during pregnancy	2.0	2.2	10.6 ***
% Amnionitis	5.4	9.6	1.4 ***
% History of kidney disease	8.8	12.1	13.5 **
% History of heart disease	3.6	4.4	6.7 *
% Hypertension (delivery history)	8.2	19.4	26.9 ***
% Diabetes (delivery history)	2.9	8.4	14.9 ***

* $p \leq .05$ comparing all three groups.

** $p \leq .001$ comparing all three groups.

*** $p \leq .0001$ comparing all three groups.

(24.3 years), followed by the group with ruptured membranes (25.6 years), and the intact membranes group (26.3 years). The differences between the VAG and CRM groups were due primarily to differences between the blacks (23.9 versus 25.3 years, $p \leq 0.001$), and entirely from the blacks for the CRM/CIM comparison (23.3 versus 26.1 years, $p \leq 0.05$). Mean years of education were comparable for the VAG and CIM groups, and the two Cesarean section groups were comparable. However, even though the mean years of education were equal for the two Cesarean section groups (12.1 years), when each group was compared against the VAG group, the CRM was found to be significantly different from the VAG group. This finding can be attributed to the differences in sample sizes and that the variances were equal only for the VAG and CRM groups of women.

The women who required a Cesarean section were approximately 3 times as likely to have some type of commercial medical insurance than those who delivered vaginally. Women in the CRM group were about 3 times as likely, and the CIM group 5 times as likely as women in the VAG group to have had a previous Cesarean section. These differences were comparable across

Table 13. Comparison of maternal characteristics of women experiencing either a vaginal deliver or a Cesarean section with ruptured fetal membranes

		TYPE OF DELIVERY	
		Vaginal (n = 5,893)	Cesarean ruptured membrane (n = 1,258)
% Race	White	34.6	38.1
	Black	64.9	61.5
	Other	0.5	0.4
% Marital status	Single	54.1	48.1
	Married	37.4	44.8
	Divorced	4.2	3.5
	Separated	4.1	3.3
	Widowed	0.3	0.2 ***
Mean maternal age		24.3	25.6 ***
Mean years of education		11.8	12.1 **
% w/ Medical coverage	Insured	11.9	30.5
	Indigent	88.1	69.5 ***
% Previous C-section		2.3	6.7 ***
Mean hours of labor		15.7	20.6
Mean birth weight (gms)		3041.9	2796.1 ***
Mean gestational age (weeks)		37.7	36.5 ***
% Pre-term delivery		21.3	37.4 ***
% Post-term delivery		0.5	1.0 *
% Multiple births		8.7	13.2 ***
% Smoked during pregnancy		19.3	15.8 *
% Alcohol use during pregnancy		10.9	7.7 **
% Any history of drug use		8.3	6.1 *
% Anomalies		1.8	5.1 ***
% History of venereal disease		1.2	1.4
% Maternal infection during pregnancy		8.3	7.9

Table 13. - Continued.

	TYPE OF DELIVERY	
	Vaginal (n = 5,893)	Cesarean ruptured membrane (n = 1,258)
% Urinary tract infection during pregnancy	2.0	2.2
% Amnionitis	5.4	9.6 ***
% History of kidney disease	8.8	12.1 *
% History of heart disease	3.6	4.4
% Hypertension (delivery history)	8.2	19.4 ***
% Diabetes (delivery history)	2.9	8.4 ***

*p ≤.05

**p ≤.001

***p ≤.0001

the races. The mean length of labor was comparable for the VAG and CRM groups (Table 13), but the time was significantly shorter for the CIM group, regardless of the comparison group (Tables 14, 15).

There was a downward trend in both mean birth weight and gestational age at delivery, with the highest being the vaginal delivery group, followed by Cesarean sections with ruptured membranes, and, finally the study group of Cesarean sections without ruptured membranes. When comparing these groups, however, it must be noted that the averages for the vaginal and Cesarean section with ruptured membranes would reflect the age when the fetus actually was instigating labor and delivery. Many of those in the intact membrane groups had an iatrogenic gestational age, reflective of when the physician decided to deliver the fetus, regardless of whether or not that would have been the actual time at which the fetus would have been delivered naturally, without intervention. This point may also help explain the increasing proportion of preterm births in the groups. Although the proportion of post term (>42 weeks) deliveries was comparable between the two Cesarean section groups, there was an approximately 2-fold increase over that seen in the vaginal deliveries.

Table 14. Comparison of maternal characteristics of women experiencing either a vaginal delivery or a Cesarean section with intact fetal membranes

		TYPE OF DELIVERY	
		Vaginal (n = 5,893)	Cesarean intact membrane enrolled (n = 645)
% Race	White	34.6	47.4
	Black	64.9	52.2
	Other	0.5	0.4 ***
% Marital status	Single	54.1	40.8
	Married	37.4	50.4
	Divorced	4.2	4.2
	Separated	4.1	4.4
	Widowed	0.3	0.2 ***
Mean maternal age		24.3	26.3 ***
Mean years of education		11.8	12.1
% w/ Medical coverage	Insured	11.9	32.0
	Indigent	88.1	68.0 ***
% Previous C-sec		2.3	12.3 ***
Mean hours of labor		15.7	11.3 *
Mean birth weight (gms)		3041.9	2662.3 ***
Mean gestational age (weeks)		37.7	36.1 ***
% Pre-term delivery		21.3	44.3 ***
% Post-term delivery		0.5	0.9
% Multiple births		8.7	5.6 *
% Smoked during pregnancy		19.3	25.6 **
% Alcohol use during pregnancy		10.9	10.1
% Any history of drug use		8.3	3.9 *
% Anomalies		1.8	6.7 ***
% History of venereal disease		1.2	14.8 ***

Table 14. - Continued.

	TYPE OF DELIVERY	
	Vaginal (n = 5,893)	Cesarean intact membrane enrolled (n = 645)
% Maternal infection during pregnancy	8.3	6.5
% Urinary tract infection during pregnancy	2.0	10.6 ***
% Amnionitis	5.4	1.4 ***
% History of kidney disease	8.8	13.5 *
% History of heart disease	3.6	6.7 *
% Hypertension (delivery history)	8.2	26.9 ***
% Diabetes (delivery history)	2.9	14.9 ***

* $p \leq .05$ ** $p \leq .001$ *** $p \leq .0001$

There was a higher proportion of multiple births comparing Cesarean sections with ruptured membranes to vaginal deliveries, and a smaller proportion when comparing Cesarean section with intact membranes population to the vaginal delivery population.

There was an increased proportion of women who smoked during their pregnancy in the intact membrane group as opposed to the other two groups, and a slight decrease in a history of drug abuse. The regular use of alcohol during pregnancy varied greatly among the three groups. There was a 2.8- to 3.7-fold increase in fetal anomalies in the Cesarean section groups as compared to the vaginal delivery group. The history of venereal disease was increased in the women with intact membranes (8.9%) as compared to the other two groups (1.2% for vaginal deliveries and 1.4% for Cesarean section with ruptured membranes). The history of urinary tract infections during the pregnancy was increased 5-fold in the intact membrane group when compared to the other two groups. Amnionitis was increased in the group who had a section with rupture of membranes and decreased in the intact membrane group, when compared to the vaginal delivery

Table 15. Comparison of maternal characteristics of women experiencing a Cesarean section delivery with or without intact fetal membranes

		TYPE OF DELIVERY	
		Cesarean ruptured membrane (n = 1,258)	Cesarean intact membrane enrolled (n = 645)
% Race	White	38.1	47.4
	Black	61.5	52.2
	Other	0.4	0.4 ***
% Marital status	Single	48.1	40.8
	Married	44.8	50.4
	Divorced	3.5	4.2
	Separated	3.3	4.4
	Widowed	0.2	0.2
Mean maternal age		25.6	26.3 *
Mean years of education		12.1	12.1
% w/ Medical coverage	Insured	30.5	32.0
	Indigent	69.5	68.0
% Previous C-sec		6.7	12.3 **
Mean hours of labor		20.6	11.3 **
Mean birth weight (gms)		2796.1	2662.3 *
Mean gestational age (weeks)		36.5	36.1
% Pre-term delivery		37.4	44.3 *
% Post-term delivery		1.0	0.9
% Multiple births		13.2	5.6 ***
% Smoked during pregnancy		15.8	25.6 ***
% Alcohol use during pregnancy		7.7	10.1
% Any history of drug use		6.1	3.9
% Anomalies		5.1	6.7
% History of venereal disease		1.4	14.8 ***
% Maternal infection during pregnancy		7.9	6.5

Table 15. - Continued.

	TYPE OF DELIVERY	
	Cesarean ruptured membrane (n = 1,258)	Cesarean intact membrane enrolled (n = 645)
% Urinary tract infection during pregnancy	2.2	10.6 ***
% Amnionitis	9.6	1.4 ***
% History of kidney disease	12.1	13.5
% History of heart disease	4.4	6.7
% Hypertension (delivery history)	19.4	26.9 ***
% Diabetes (delivery history)	8.4	14.9 ***

* p ≤ .05

** p ≤ .001

*** p ≤ .0001

group. The history of other maternal infections excluding urinary tract infections during the pregnancy, such as respiratory infections, vaginitis, and tuberculosis during the pregnancy, was comparable for all of the groups.

There was a increase in the prevalence of kidney disease in women who experienced a Cesarean section compared to the vaginal delivery group. The women who were delivered with an intact membrane had between 1.5 and 2 times the amount of reported heart disease, as compared to either of the other two groups. Using the vaginal delivery group as a baseline, there was a 2.4-fold increase in the proportion of women with reported hypertension at the time of delivery in the women in the ruptured membrane group, and a 3.3-fold increase in the women in the enrolled intact membrane group. There was a 3- to 4-fold increase in diabetes at delivery for the Cesarean delivery groups compared to the vaginal delivery group.

Of the 169 appropriate deliveries missed, information was available only for those that occurred during the last 2 full years of the study (1989 and 1990, N = 76). The only characteristics

for which the enrolled and missed groups differed were mean gestational age ($p \leq .001$), mean birth weight ($p \leq .05$), percent preterm delivery ($p \leq .05$), and percent multiple births ($p \leq .0001$) (Table 16).

Validation of Complication Status

A 20% random sample of all records that were marked negative in all of the possible variable fields for each complication was selected for full medical record review to determine if there was any evidence of diabetes or hypertension present. Of the 27 records examined, none showed any evidence of misclassification. All records with either any indication of a complication or a negative status with missing data were reviewed to ascertain complication status. Of the 411 women listed as non-diabetic, 1 was positive (0.24%), and of the 313 non-hypertensive cases, 3 actually were hypertensive (0.96%). If we make the assumption that all of the 139 cases that were completely filled out as negative actually were negative, the false negative rate for diabetes was 0.18%, and for hypertension, the rate was 0.66%. There were 2 false positive diabetes cases out of 95 listed cases, for a false positive rate of 2.11%, and 12 cases misclassified out of 193 hypertensives, for a rate of 6.22%. Final analysis was conducted on the corrected diabetic and hypertensive status.

Risk of Placental Infection with *Ureaplasma urealyticum*

Chi-square tests were done based on the mother's status for the given variable and whether or not she delivered one or more placenta that tested positive for *Ureaplasma urealyticum* (Table 17). The Fisher's exact test was used when 20% or more of the expected cell frequencies were < 5 . Two Asians and 1 Hispanic were deleted from this analysis. Race; socioeconomic status, as measured by either education or insurance status; smoking during pregnancy; and the presence of diabetes were not significantly associated with placental infection. Spontaneous delivery (type of delivery) was defined as a delivery in which spontaneous labor was the reason for performing the Cesarean section. Spontaneous delivery was compared against an indicated delivery, in which the physician made the decision to deliver the fetus, either with or without induction of labor, as in the case of fetal distress or fetopelvic disproportion.

Table 16. Population characterization of women eligible for enrollment in the study between October 26, 1987 and December 31, 1990

		Enrolled (n = 646)	Missed (n = 76)
% Race	White	47.3	39.5
	Black	52.2	60.5
% Marital status	Single	40.8	41.9
	Married	50.4	50.0
	Divorced	4.2	4.1
	Separated	3.5	4.1
	Widowed	0.3	0.0
Mean maternal age		26.3	26.7
Mean years of education		12.1	11.9
% w/ Medical coverage	Insured	32.0	37.0
	Indigent	68.0	63.0
% Previous C-sec		11.7	16.1
Mean hrs labor		11.3	28.6
Mean birth weight		2662.3	2375.2 *
Mean gestational age		36.1	34.2 **
% Preterm		44.5	61.8 *
% Post maturity		0.9	1.3
% Multiple births		5.6	19.7 ***
% Smokers		25.6	26.8
% Alcohol use		10.1	15.0
% Drug use		3.9	5.0
% Anomalies		6.7	4.0
% Venereal disease		14.9	19.5
% Maternal infection		6.5	9.2
% Urinary tract infection		10.6	5.0
% Amnionitis		1.4	2.7

Table 16 - Continued.

	Enrolled (n = 646)	Missed (n = 76)
% Kidney disease	13.5	10.0
% Heart disease	6.7	7.5
% Hypertension (delivery history)	26.2	21.6
% Diabetes (delivery history)	11.3	9.2

* $p \leq .05$ ** $p \leq .001$ *** $p \leq .0001$

Among non-diabetic women, 12.4% had at least one placenta infected with Ureaplasma urealyticum, compared against 7.3% of all diabetic women ($p = .151$). This comparison did not control for hypertensive status. Normotensive women had a prevalence of 13.8%, women with any type of hypertension had a prevalence of 6.4%, without adjustment for diabetes ($p = .007$).

Among normotensive, non-diabetic women, 14.4% delivered at least one infected placenta, compared to 9.3% of the women with only diabetes, 6.8% of the women with only hypertension, and 4.8% of the women who had both complications (Figure 3). When the individual hypertensive classifications were considered, 8.0% of the women with acute (pregnancy induced) hypertension, 5.6% of those with chronic hypertension, and none of those with acute superimposed on chronic hypertension developed an infected placenta compared against 13.8% of those women who were normotensive (Figure 4).

Multivariate Analysis for the Prediction of Placental Infection with Ureaplasma

For the initial analysis using univariate logistic regression (Table 18) to explore the association between placental infection with U. urealyticum and the individual maternal characteristics, the three non-black/non-white individuals were excluded from the analysis of the race variable. Because race was not significantly associated with infection, these three women were re-entered into the group for purposes of multivariate logistic regression model building. A test for trend for hours of labor and gestational age was included as part of the final model. No attempt

Table 17. Odds ratios, chi-square, and Fisher's exact tests for placental infection with Ureaplasma, given selected maternal characteristics

Variable		Percent positive (number)	Odds ratio	Confidence interval (95%)	P-value
Spontaneous delivery	no	6.06 (28)			
	yes	25.68 (47)	5.36	3.23, 8.89	< .001
Race	white	10.49 (32)			
	black	12.76 (43)	1.25	0.75, 2.09	.441
Maternal age (years)	>19	10.18 (57)			
	<20	21.18 (18)	2.37	1.32, 4.27	.003
Hours of labor	none	5.84 (23)			
	1 - 6	16.46 (13)	3.18	1.44, 6.95	< .003
	7 - 12	14.29 (7)	2.68	1.08, 6.10	.036 §
	13 - 24	17.39 (8)	3.38	1.43, 7.50	.009 §
	>24	37.50 (21)	9.69	4.62, 20.33	< .001
Hours of labor	<25	9.17 (54)			
	>24	37.50 (21)	5.94	3.23, 10.93	< .001
Gestational age (weeks)	>36	6.69 (24)			
	30 - 36	16.35 (26)	2.73	1.45, 5.12	.001
	<30	28.21 (22)	5.48	2.75, 10.96	< .001
Gestational age (weeks)	>29	9.65 (50)			
	<30	28.56 (22)	3.68	2.07, 6.52	< .001
Previous pre-term delivery	no	7.05 (26)			
	yes	17.82 (49)	2.86	1.73, 4.74	< .001
Primigravida	no	8.97 (35)			
	yes	15.38 (36)	1.84	1.12, 3.03	.015
Uninsured	no	11.11 (15)			
	yes	12.89 (37)	1.18	0.63, 2.24	.604
Education (years)	<8	9.95 (22)			
	>7	13.33 (2)	1.39	0.21, 4.82	.655 §
Smoked during pregnancy	no	10.11 (37)			
	yes	14.29 (18)	1.48	0.81, 2.71	.199
Marital status	married †	8.68 (29)			
	single ‡	18.97 (44)	2.46	1.49, 4.07	< .001
Multiple birth this delivery	no	9.85 (60)			
	yes	41.67 (15)	6.30	3.33, 15.55	< .001 §

Table 17. - Continued

Variable		Percent positive (number)	Odds ratio	Confidence interval (95%)	P-value
Other bacteria isolated	no	8.29 (46)			
	yes	32.22 (29)	5.26	3.08, 8.98	< .001
Diabetes mellitus	no	12.39 (68)			
	yes	7.29 (7)	0.56	0.25, 1.25	.151
Hypertension	no	13.82 (63)			
	yes	6.35 (12)	0.42	0.22, 0.80	.007
Elevated pressure during pregnancy	no	13.47 (64)			
	yes	6.47 (11)	0.44	0.23, 0.86	.015
Chronic hypertension	no	12.68 (72)			
	yes	3.90 (3)	0.28	0.09, 0.91	.024
Acute hypertension	no	12.94 (66)			
	yes	6.67 (9)	0.48	0.23, 0.99	.043

§ Fisher's exact test

† Married, separated or divorced

‡ Single, widowed, other

was made to control for the degree of control of the complications of interest because this information was both poorly characterized and subjective.

Testing was done using the mother's characteristic and her overall Ureaplasma infection status. Marital status, labor class, gestational age class, type of delivery, and primigravida delivery were no longer significant when entered into the full model. Marital status and primagravida were removed from the model. Type of delivery, labor class, and gestational age class were kept in the final model because these factors have been shown to be associated with infection (unpublished data). Previous preterm delivery was also retained in the final model, because there was an association with preterm delivery; previous preterm deliveries may have been due to placental infection with Ureaplasma.

The final models used are detailed in Table 19. The core group of variables remained the same but the factors of interest (diabetes and hypertension) were changed to give four separate models. Because almost half of the diabetics also had some form of hypertension during their




Figure 3. Placental infection status with Ureaplasma urealyticum by complication classification.




Figure 4. Placental infection status with Ureaplasma urealyticum by hypertensive classification.

pregnancy, the first model separates the factors into either factor alone and both factors together. The second model considered any diagnosis of hypertension, the third model considered only hypertension based on experiencing an elevated blood pressure during the pregnancy, and the final model considered the two classes of hypertension (acute and chronic). From this last model, a risk estimate for experiencing both types of hypertension was calculated. The confidence intervals for this estimate were calculated under the assumption of non-independence.

Table 18. Significant odds ratio estimates for placental infection with Ureaplasma urealyticum by univariate logistic regression

Variable	Odds ratio	(CI ₉₅ : L,U)	p-value
Spontaneous delivery	5.36	(3.23, 8.89)	< <.001
Labor >24 hours	5.94	(3.23, 10.89)	< <.001
Gestational age <30 weeks	3.68	(2.07, 6.52)	< <.001
Previous pre-term delivery	2.86	(1.73, 4.74)	< <.001
Multiple birth this delivery	6.54	(3.20, 13.35)	< <.001
Mother's age <20 years	2.37	(1.32, 4.27)	.004
Other bacteria isolated from placenta	9.53	(5.65, 16.10)	< <.001
Diabetes	0.56	(0.25, 1.25)	.156
Hypertension	0.42	(0.22, 0.80)	.008
Elevated blood pressure during pregnancy	0.44	(0.23, 0.86)	.017
Chronic hypertension	0.28	(0.09, 0.91)	.034
Acute hypertension	0.48	(0.23, 0.99)	.047

The odds ratio for placental infection with Ureaplasma, given a woman had some form of diabetes during her pregnancy, was 1.34 (CI₉₅ = 0.47, 3.80; p = 0.588) (Table 20, Figure 5).

These results control for the core variables and hypertension in any form, and indicate that there is no association between maternal diabetes and placental infection with Ureaplasma urealyticum.

Controlling for diabetes as well as the core variables, the odds ratio for placental infection, given

any type of hypertension, was 0.28 ($CI_{95} = 0.11, .72$; $p = 0.008$), indicating that there is a negative association between placental infection with U. urealyticum and maternal hypertension during pregnancy (Table 20, Figure 5).

Table 19. Logistic regression models

DEPENDENT VARIABLE =		CODING	
Placental infection with <u>Ureaplasma urealyticum</u>		yes	= 1
		no	= 0
INDEPENDENT VARIABLES (Core) =			
Type of labor:		indicated	= 0
		spontaneous	= 1
Labor class:		no labor	= 0
		1 - 6 hours	= 1
		7 - 12 hours	= 2
		13 - 24 hours	= 3
		>24 hours	= 4
Gestational age:		>36 weeks	= 0
		30 - 36 weeks	= 1
		<30 weeks	= 2
Multiple births this delivery		no	= 0
		yes	= 1
Maternal age		> 19 years	= 0
		<20 years	= 1
History of previous preterm delivery		no	= 0
		yes	= 1
Any other bacteria isolated from the placenta this delivery		no	= 0
		yes	= 1
INDEPENDENT VARIABLES (Model) =			
Model 1.	Hypertension only	no	= 0
		yes	= 1
	Diabetes only	no	= 0
		yes	= 1
	Diabetes with hypertension	no	= 0
		yes	= 1
Model 2.	Any diagnosis of hypertension	no	= 0
		yes	= 1

✓

Table 19 - Continued.

Model 3.	Any elevated blood pressure during current pregnancy	no yes	= 0 = 1
INDEPENDENT VARIABLE =		CODING	
Model 4.	Chronic hypertension	no yes	= 0 = 1
	Acute (pregnancy induced) hypertension	no yes	= 0 = 1
	Acute superimposed on chronic hypertension	no yes	= 0 = 1

Because no association was found between diabetes and infection, analysis of the relationship between placental infection with Ureaplasma and hypertension was done without controlling for this factor (Table 21). When all hypertensive classifications were considered as a group, the odds ratio for any placental infection with Ureaplasma for a given pregnancy was 0.30 ($CI_{95} = 0.13, 0.71$; $p = 0.006$). The odds ratio was the same if a woman was classified as hypertensive only if she experienced an elevated blood pressure during her pregnancy (0.30, $CI_{95} = 0.13, 0.72$; $p = 0.007$) (Figure 6). When evaluating pregnancy outcome based on the type of hypertension experienced, the odds ratios were 0.57 ($CI_{95} = 0.15, 2.15$; $p = 0.410$) for chronic hypertension, 0.29 ($CI_{95} = 0.11, 0.76$; $p = 0.012$) for acute hypertension, and 0.26 ($CI_{95} = 0.03, 2.38$; $p = 0.248$) for those with both types of hypertension (Figure 6). Because all of the individuals in this last group were negative for Ureaplasma, one individual was randomly chosen to be assigned as positive for this model only, so that an estimate and confidence interval could be obtained. Without this adjustment, the odds ratio was zero, with an infinite upper limit.

Table 20. Odds ratio estimates for placental infection with Ureaplasma urealyticum by multivariate logistic regression, Model I

Variable		Odds ratio	(CI ₉₅ : L,U)	p-value
Spontaneous delivery		1.42	(0.56, 3.60)	.455
Labor hours	1-6	1.29	(0.97, 1.71)	.075 †
	7-12	1.66	(0.95, 2.91)	
	13-24	2.15	(0.93, 4.97)	
	>24	2.77	(0.90, 8.49)	
Gestational age (weeks)	30-36	1.69	(0.96 2.98)	.068 †
	<30	2.86	(0.92, 8.87)	
Previous pre-term delivery		1.66	(0.71, 3.90)	.243
Multiple birth this delivery		5.30	(2.12, 13.29)	<.001
Mother <20 years of age		2.35	(1.14, 4.81)	.021
Other bacteria isolated from placenta		4.05	(2.09, 7.84)	<<.001
Diabetes only		1.34	(0.47, 3.80)	.588
Hypertension only		0.28	(0.11, 0.72)	.008
Diabetes with hypertension		0.48	(0.10, 2.30)	.360

† Test for trend




Figure 5. Odds ratios for placental infection with Ureaplasma urealyticum associated with diabetes only or hypertension only.

Table 21. Odds ratio estimates for placental infection with Ureaplasma urealyticum for various hypertension classifications using multivariate logistic regression, Models II - IV

Variable	Any diagnosis of hypertension			Elevated blood pressure in pregnancy			By sub-classification of hypertension		
	OR	(CI ₉₅ : L,U)	p-value	OR	(CI ₉₅ : L,U)	p-value	OR	(CI ₉₅ : L,U)	p-value
Spontaneous delivery	1.37	(0.54, 3.45)	.506	1.42	(0.57, 3.56)	.456	1.44	(0.55, 3.60)	.436
Labor hours									
1-6	1.31	(0.99, 1.73)		1.32	(0.99, 1.74)		1.28	(0.97, 1.68)	
7-12	1.71	(0.97, 3.00)		1.73	(0.98, 3.04)		1.63	(0.94, 2.83)	
13-24	2.23	(0.96, 5.18)		2.28	(0.98, 5.31)		2.08	(0.91, 4.77)	
>24	2.91	(0.95, 8.97)	.063 *	2.99	(0.97, 9.25)	.057	2.65	(0.88, 8.03)	.084
Gestational age (weeks)									
30-36	1.64	(0.94, 2.87)		1.62	(0.93, 2.81)		1.66	(0.95, 2.89)	
<30	2.70	(0.89, 8.26)	.081 *	2.61	(0.86, 7.90)	.090	2.74	(0.90, 8.33)	.075
Previous preterm delivery	1.67	(0.72, 3.92)	.235	1.67	(0.71, 3.90)	.237	1.73	(0.75, 4.00)	.200
Multiple birth this delivery	5.08	(2.47, 10.44)	< .001	5.00	(2.03, 12.34)	< .001	5.00	(2.03, 12.34)	< .001
Mother <20 years of age	2.32	(1.13, 4.77)	.022	2.39	(1.16, 4.92)	.019	2.34	(1.12, 4.84)	.023
Other bacteria isolated from placenta	3.92	(2.04, 7.56)	<< .001	3.90	(2.03, 7.50)	<< .001	3.78	(2.22, 6.43)	<< .001

Table 21. Continued.

Variable	Any diagnosis of hypertension			Elevated blood pressure in pregnancy			By sub-classification of hypertension		
	OR	(CI ₉₅ : L,U)	p-value	OR	(CI ₉₅ : L,U)	p-value	OR	(CI ₉₅ : L,U)	p-value
Any hypertension	0.30	(0.13, 0.71)	.006						
Elevated blood pressure during pregnancy				0.30	(0.13, 0.72)	.007			
Chronic hypertension							0.57	(0.15, 2.15)	.410
Acute hypertension							0.29	(0.11, 0.76)	.012
Acute superimposed on chronic hypertension							0.26	(0.03, 2.38)	.248 **

* Test for trend

** Zero cell gives an odds ratio of zero, maximum odds ratio and CI₉₅ derived by random assignment of Ureaplasma positive status to one of the women with acute hypertension superimposed on chronic hypertension




Figure 6. Odds ratios for placental infection with Ureaplasma urealyticum by hypertension classification.




Figure 7. Odds ratios for placental infection with any bacteria associated with elevated blood pressure during pregnancy.

CHAPTER 5

DISCUSSION

Diabetes

The preceding analysis indicates that, in the case of diabetes, there is no evidence to conclude that there is an association, either positive or negative, between diabetes and placental infection with Ureaplasma urealyticum. This is not in agreement with the studies that found an increase in infection rates of other bacteria in diabetic women both during and after a pregnancy.^{27, 30, 76} The study involving post-Cesarean section infection²⁷ did not characterize the types of organisms isolated from the infections, whereas the antepartum studies were concerned specifically with Group B Streptococcus (GBS),^{30, 76} an organism of particular concern due to its association with neonatal infections.^{29, 30, 69} Studies of Group C and Group G Streptococcal infections found 23%¹⁰⁸ and 14%¹³⁰ of cases, respectively, were associated with diabetic patients. It was hypothesized that the increased availability of glucose in these patients favored the fermentative metabolism of these streptococci.⁷⁶ This situation may counterbalance any aberration in the rates of protein synthesis and degradation in both the placenta and fetus, removing any advantage to the Ureaplasma. This could be accomplished by giving the streptococci a competitive edge early on in colonization and competition for additional nutrients, or the byproducts of the fermentative process could alter the maternal physiological environment enough to make it unfavorable to the Ureaplasmas.

Analysis of the data in this study would indicate that, if any of these situations existed, they either did not confer an advantage to the Ureaplasma, or that other factors associated with the hypertensive conditions induced a stronger protective effect.

Hypertension

Both human and animal studies have demonstrated a reduction in placental blood flow during hypertensive pregnancies.^{1, 2, 13, 39, 63, 68, 77, 85, 88, 116} This reduction has been determined through both the measurement of uteroplacental blood flow rates^{1, 2, 13, 68, 77, 85} and evaluation of placental pathology criteria.^{39, 63, 88, 116} Hallmark features of the placental pathology associated with reduced blood flow were inadequate transformation of uteroplacental spiral arteries and acute atherosclerosis. The same features also were found to be associated with preterm delivery⁸⁸ and fetal growth retardation.^{14, 39, 116} The pathology was seen with these adverse outcomes even in the absence of a measured abnormal increase of blood pressure during the pregnancy.^{14, 88, 116} Flow rate reduction attributed to hypertension ranged from 23-60% of normal.^{1, 13, 17} When clearance time from the placental bed of radioactive sodium chloride (²⁴NaCl) was measured as a surrogate for blood flow, the clearance rates for mildly and severely pre-eclamptic women, compared to normotensive pregnant women was 1.9 and 3.7 times greater, respectively.

The reduction of the flow rate in the uteroplacental complex would naturally lead to a reduction in the amount of nutrients available to the fetus for growth. Although a normal placenta has an excess capacity, compared to need, of up to 50%,^{1, 77} the reduction of the nutrient supply could also adversely affect the ability of Ureaplasma to thrive in the placental environment. If this were the case, there should also be a reduction in the proportion of placentas infected with other bacteria. Accordingly, the odds ratios, using placental infection with bacteria other than Ureaplasma and placental infection with either Ureaplasma or other bacteria as the dependent variable, were calculated (Figure 7) for women who experienced an elevated blood pressure during pregnancy. Although the odds ratio for bacteria other than Ureaplasma was <1, it was not significantly reduced compared to women without an abnormal increase in blood pressure (0.84, CL₉₅ = 0.44, 1.60; p = 0.593). When any type of bacterial infection was considered, the odds ratio was significantly reduced (0.48, CL₉₅ = 0.27, 0.88; p = 0.018).

A total of 21 other species of bacteria were isolated from the placentas of the 645 women in this study. Ureaplasma urealyticum was the single most frequently isolated organism in this study (n = 75), followed by Peptostreptococcus species (n = 24), Mycoplasma hominis (n = 22),

Gardnerella vaginalis (n = 21), Streptococcus species (n = 18), and Propionibacterium species (n = 15). All other species had <10 isolations each. When comparing the distributions of the above mentioned organisms in women with and without an abnormally elevated blood pressure during their pregnancy, M. hominis (1.8 versus 4.0%), G. vaginalis (2.4 versus 3.6%), Streptococcus species (2.9 versus 2.7%), and Propionibacterium species (2.9 versus 2.1%) showed no significant differences. Only Peptostreptococcus species (0.59 versus 4.8%) showed a significant reduction in prevalence. A failure to detect a reduction may be a reflection of having too small a sample size to detect a difference in these other organisms, either individually or pooled.

Neither the age of the mother nor SES impacted on the risk of hypertension in general. Although the logistic regression model controlled for the relationship between age and Ureaplasma infection, the relationship between hypertension and age could have confounded the results. However, when considering any diagnosis of hypertension and age, 32.4% of those under the age of 20 (n = 85) were hypertensive, compared to 28.8% of those over the age of 20 (n = 560, 2-tailed X^2 , p = 0.429). Chronic hypertension was significantly reduced in the younger women (1.2 vs. 13.6%, 2-tailed X^2 , p < 0.001), whereas the younger women were almost twice as likely to experience pregnancy-induced hypertension (32.9 vs. 19.1%, 2-tailed X^2 , p < 0.01). If a measured abnormal elevation of blood pressure during pregnancy is considered, the younger women were comparable to the older women (32.9 vs. 25.4.1%, 2-tailed X^2 , p = 0.15). The proportions of women with hypertension in the low and high SES groups were not significantly different, regardless of the classification of hypertension used. Because an actual abnormal elevation of blood pressure during pregnancy seems to be the driving force in the reduced risk of placental infections, it would appear that neither age nor SES have any affect on the risk of measured hypertension during pregnancy in this population.

Additional Findings

The finding that smoking was not associated with Ureaplasma infection of the placenta in this study population was contradictory to previously published findings.^{67, 80} This could have been due to the fact that smoking was a risk factor for having a Cesarean section delivery with intact

membranes, as seen by the significant increase in the proportion of smokers in this group as compared to either of the other delivery groups (Tables 12, 14, and 15).

Primigravida and marital status were no longer significant in the multivariate models because these factors were tied heavily to maternal age, with women <20 years of age more likely to be primigravida for the current delivery (OR, 6.66, CI₉₅ 3.94, 11.25), and more likely to be single (OR, 2.78, CI₉₅ 1.68, 4.59).

Although spontaneous delivery was no longer significant in the final multivariate models, it was retained because Ureaplasma has been shown to be a risk factor for very early preterm delivery (>30 weeks gestational age) among spontaneous, but not indicated deliveries in this population (data not shown). Ureaplasma may act in some way to initiate early labor and, therefore, spontaneous delivery, as earlier defined, could act as a marker for placental infection, at least among low gestational age deliveries.

The significant association of length of labor and placental infection with Ureaplasma is consistent with other studies and is most probably due to a combination of the dilation of the cervix, allowing freer access of the flora of the lower genital tract to the uterus and placenta, and the wicking of mucus and fluids into the uterus as the contractions of labor continue. The longer the labor, the better the chance the organisms that have been drawn up into the uterus have of colonizing the uteroplacental environment.

The finding of previous preterm delivery being significantly associated with placental infection with Ureaplasma would be consistent with the finding of the association between low gestational age at delivery and Ureaplasma infection. Ureaplasma infection could indicate a chronic infection of the uterine environment. Even if the current delivery was not preterm, or very preterm, the Ureaplasma could be present, but its activity suppressed due to the mother's immune response to a chronic infection.

The association between placental infection with Ureaplasma and maternal age <20 years is consistent with the studies previously cited. Why this should be the case is unclear, in light of the fact that risk of infection increases with the total number of sexual partners, and it would be expected that women <20 years of age would have had fewer partners than women over the age of

20. It may be that the hormonal or immune status of the women, or the composition of the vaginal flora may simply make it easier for the Ureaplasma to colonize the endocervical environment. Another possibility might be that beginning sexual activity at an earlier age may increase the likelihood of having multiple partners. Further studies in this area would be useful.

The finding of an association between multiple gestation and placental infection with U. urealyticum was surprising. It is certainly unclear as to what conditions associated with a multiple delivery would be advantageous for movement of the organism up into the placenta. If, in fact, the reduced risk of infection in the presence of an abnormally increased blood pressure is due to a decrease in the blood flow, then it may be possible that an increased demand for blood in the multiple delivery may increase the risk of infection. Another possible explanation may be that there is an increased pressure on the cervix due to larger than usual contents of the uterus, which over the course of the pregnancy may cause some stretching of the cervical opening, allowing the organism to be wicked up into the uterus. This could also explain the finding that in vaginal deliveries of multiple gestations, only the first born of the sets of twins discussed were infected with either Ureaplasma or Mycoplasma.⁶⁴

The strong association between placental infection with other bacteria and Ureaplasma should not be surprising. Any event that would allow a breach of what is essentially a sterile environment by one bacterium should allow any others that are present in the lower genital tract at that time to also move up into the uteroplacental environment. A general contamination of this environment would be an event marker, and the distribution of the species found could reflect either their distribution in the lower tract, or their varying ability to maintain colonization once they have moved into the new environment.

Sexual Activity Prior to and During Pregnancy

Information of the mother's sexual activity was not available for analysis in this study. Because Ureaplasma colonization and infection is a result of sexual activity, knowledge of the type and extent of activity would be useful to determine the mothers' initial risk of infection of the lower urogenital tract. The women with and without the complications of interest could possibly differ in such characteristics as age at first intercourse, number of sexual partners, and sexual activity during

pregnancy. The severity of their illness and age of onset may alter their activity in all of these areas, and therefore decrease their overall initial risk of lower tract infection, which would be a prerequisite for the infection to move up into the placenta, the results of which would be to support the null hypothesis or produce a negative association.

Antibiotic Treatment Prior to or During Pregnancy

Antibiotic treatment prior to or during pregnancy may also differ among the two groups of women. Although an attempt was made to collect data on antibiotic use during the pregnancy and labor (if present), there is no information on antibiotic use prior to conception. Depending on the types of antibiotics used, this may decrease the mothers' risk of being infected with Ureaplasma. If there was an increase in overall infection rates with other organisms among the women with diabetes or hypertension, treatment for those infections with antibiotics active against Ureaplasma might incidentally cure an unrealized infection with Ureaplasma. This, in effect, would reduce the risk of placental infection by reducing the prevalence of lower tract infection with Ureaplasma.

Control of Medical Condition

The level of control of the patient's complication (i.e., diabetes or hypertension) may have an effect on her risk of infection. If, indeed, the metabolic conditions produced by the uncontrolled complication favor or reduce the risk of either the infection of the lower urogenital tract or the spread of Ureaplasma infection to the placenta, proper control of the condition may mask the true risk of infection due to the condition. Unfortunately, rarely does a record state categorically whether the level of control is good, poor, or nonexistent and, at best, this would be a subjective assessment that would vary from clinician to clinician. However, as previously noted, when the odds ratio was calculated for only those who had experienced an abnormal increase in blood pressure during the pregnancy, which would be a reasonable surrogate for the lack of control of the condition, it was essentially identical to that of the odds ratio for any diagnosis of hypertension.

Comparability to the General Population

Associations found in this study group may not be generalizable to the larger population of pregnant women. By and large, this is a highly selected group of high-risk pregnancies. The current policy for performance of a Cesarean section at University Hospital requires that there be a

bona fide medical reason for the procedure; elective Cesareans are not supposed to be performed, although occasionally some are performed. Although infection of the placenta implies infection of the lower genital tract, the lack of infection of the placenta by no means implies a lack of organisms in the lower tract. The ureaplasma infection status of the lower urogenital tract of these women is unknown, and, therefore, it is unknown if the risk of upper urogenital tract infection for the comparison group is the same as for the general population. If the rate is higher in our comparison group than in the general population, it may explain in part the reduction in risk for the hypertensives; whereas, if the rate is lower, the risk in the general population may be underestimated. If the infection rate of the lower genital tract of the women in the complication groups is lower than the general population, the interpretation of the odds ratios could shift from a negative association to either a null or positive association, depending on the magnitude of the difference.

Another possible source of non-comparability could arise if any of the other indications for Cesarean section were capable of enhancing Ureaplasma's ability to infect the placenta. Even if the infection rates in the lower genital tract for both the study and comparison groups were the same as that of the general population, it would be likely that, in this study population, any increase in risk due to the complications of interest may appear to be smaller than they actually are, or masked all together.

CHAPTER 6

SUMMARY

A cross-sectional study was conducted at the University Hospital of The University of Alabama at Birmingham, which included 645 of 815 (79%) Cesarean section deliveries with intact fetal membranes. The purpose of this study was to evaluate the association between maternal diabetes, maternal hypertension, and placental infection with Ureaplasma urealyticum. There were 75 women with at least one placenta showing cultural evidence of infection with Ureaplasma urealyticum. U. urealyticum was the single most frequently isolated organism in this population.

Using multivariate logistic regression to control for confounding factors, it was found that, in this population, the odds ratio for placental infection, given maternal diabetes, was 1.39 ($CI_{95} = 0.48, 4.00$), indicating that there was no association between maternal diabetes and placental infection with U. urealyticum. Odds ratios of 0.30 ($CI_{95} = 0.13, 0.71$) for any diagnosis of hypertension, 0.57 ($CI_{95} = 0.15, 2.15$) for chronic hypertension, 0.29 ($CI_{95} = 0.11, 0.76$) for pregnancy-induced (acute) hypertension, 0.26 ($CI_{95} = 0.03, 2.38$) for acute superimposed on chronic hypertension, and 0.30 ($CI_{95} = 0.13, 0.72$) for a measured abnormal increase in maternal blood pressure during pregnancy indicate a negative association between at least some forms of hypertension and placental infection with Ureaplasma urealyticum. Whether this effect was due to a reduction in the prevalence of Ureaplasma infection in the lower genital tract prior to pregnancy, or a suppression of the progression of infection during the pregnancy could not be determined in this study. However, there is evidence, both pathological and in the form of quantitative measurements, that there is a reduction of blood flow to the placenta in the presence of hypertension during pregnancy, and this may be one possible explanation for the results found in this study.

Additionally, placental infection with Ureaplasma urealyticum was found to be positively associated with increased length of labor, previous preterm delivery, maternal age of <20 years, multiple births, and placental infections with other bacteria. Additional prospective studies that would ascertain the infection status of the lower genital tract prior to pregnancy would be needed to clarify the nature of the association, as well as clarify the issue of comparability to the general population of pregnant women.

LITERATURE CITED

1. Ahokas, R.A., Reynolds, S.L., Anderson, G.D., and Lipshitz, J. Uteroplacental blood flow in the hypertensive, term pregnant spontaneously hypertensive rat. *Am J Obstet Gynecol* 1987; 156(4):1010.
2. Ahokas, R.A., and Sabai, B.M. The relationship between experimentally determined litter size and maternal blood pressure in spontaneously hypertensive rats. *Am J Obstet Gynecol* 1990; 162(3):841.
3. Barile, M.F. DNA homologies and serologic relationships among ureaplasmas from various hosts. *Pediatr Infect Dis* 1986; 5(6):S296.
4. Berman, S.M., Harrison, H.R., Boyce, W.T., Haffner, W.J.J., Lewis, M., and Arthur, J.B. Low birth weight, prematurity and post partum endometritis. Association with prenatal cervical Mycoplasma hominis and Chlamydia trachomatis infections. *JAMA* 1987; 257(9):1189.
5. Birch, D.F., Fairley, K.F., and Pavillard, R.E. Unconventional bacteria in urinary tract disease: Ureaplasma urealyticum. *Kid Inter* 1981; 19:58.
6. Black, F.T. Modifications of the growth inhibition test and its application to human T-mycoplasmas. *Applied Microbiol* 1973; 25(4):528.
7. Black, F.T., and Krogsgaard-Jensen, A. Application of direct immunofluorescence, indirect haemagglutination and polyacrylamide-gel electrophoresis to human T- mycoplasmas. *Acta Path Microbiol Scan [B]* 1974; 82:345.
8. Blanco, J.D., Gibbs, R.S., Malherbe, H., Strickland-Cholmley, M., St. Clair, P.J., and Castaneda, Y.S. A controlled study of genital mycoplasmas in amniotic fluid from patients with intra-amniotic infection. *J Infect Dis* 1983; 147(4):650.
9. Bowie, W.R., Wang, S., Alexander, E.R., Floyd, J., Forsyth, P.S., Pollock, H.M., Lin, J.L., Buchanan, T.M., and Holmes, K.K. Etiology of nongonococcal urethritis - evidence for Chlamydia trachomatis and Ureaplasma urealyticum. *J Clin Invest* 1977; 59:735.
10. Braun, P., and Besdine, R. Tuboovarian abscess with recovery of T-mycoplasma. *Amer J Obstet Gynecol* 1973; 117(6):861.
11. Braun, P., Klein, J.O., Lee, Y., and Kass, E.H. Methodologic investigations and prevalence of genital mycoplasmas in pregnancy. *J Infect Dis* 1970; 121(4):391.
12. Braun, P., Lee, Y., Klein, J.O., Marcy, S.M., Klein, T.A., Charles, D., Levy, P., and Kass, E.H. Birth weight and genital mycoplasmas in pregnancy. *New Engl J Med* 1971; 284(4):167.

13. Brinkman, C.R., Nuwayhid, B., and Assali, N.S. Renal hypertension and pregnancy in sheep. I. Behavior of uteroplacental vasomotor tone during mild hypertension. *Amer J Obstet Gynecol* 1975; 121(8):931.
14. Brosens, I., Dixon, H.G., and Robertson, W.B. Fetal growth retardation and the arteries of the placental bed. *Brit J Obstet Gynaecol* 1977; 84:656.
15. Brown, M.B., Cassell, G.H., Taylor-Robinson, D., and Shephard, M.C. Measurement of antibody to Ureaplasma urealyticum by an enzyme-linked immunosorbent assay and detection of antibody responses in patients with nongonococcal urethritis. *J Clin Microbiol* 1983; 17(2):288.
16. Brunner, H., Weidner, W., and Schiefer, H. Quantitative studies on the role of Ureaplasma urealyticum in non-gonococcal urethritis and chronic prostatitis. *Yale J Biol Med* 1983; 56:545.
17. Brunner, H., Weidner, W., and Schiefer, H. Studies on the role of Ureaplasma urealyticum and Mycoplasma hominis in prostatitis. *J Infect Dis* 1983; 147(5):807.
18. Canavan, J.P., and Goldspink, D.F. Maternal diabetes in rats. II. Effects on fetal growth and protein turnover. *Diabetes* 1988; 37:1671.
19. Caspi, E., Solomon, F., Langer, R., and Somplinsky, D. Isolation of Mycoplasma from the placenta after Cesarean section. *Obstet Gynecol* 1976; 48(6):682.
20. Caspi, E., Solomon, F., and Sompolinsky, D. Early abortion and Mycoplasma infection. *Israel J Med Sci* 1972; 8(2):122.
21. Cassell, G.H., Davis, R.O., Waites, K.B., Brown, M.B., Marriott, P.A., Stagno, S., and Davis J.K. Isolation of Mycoplasma hominis and Ureaplasma urealyticum from amniotic fluid at 16-20 weeks of gestation: Potential effect on outcome of pregnancy. *Sex Trans Dis* 1983; 10(4):294.
22. Cassell, G.H., Waites, K.B., Crouse, D.T., Rudd, P.T., Canupp, K.C., Stagno, S., and Cutter, G.R. Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birthweight infants. *Lancet* 1988; 2:240.
23. Cassell, G.H., Younger, J.B., Brown, M.B., Blackwell, R.E., Davis, J.K., Marriott, P., and Stagno, S. Microbiologic study of infertile women at the time of diagnostic laparoscopy: Association of Ureaplasma urealyticum with a defined sub-population. *New Engl J Med* 1983; 308(9):504.
24. Crăcea, E., Botez, D., Constantinescu, S., and Georgescu-Brăila, M. Ureaplasma urealyticum serotypes isolated from cases of female sterility. *Zbl Bakt Hyg I Abt Orig A* 1982; 252:535.
25. Csonka, G.W., Williams, R.E.O., and Corse, J. T-mycoplasma in non-gonococcal urethritis. *Lancet* 1966; 1:1292.
26. Davey, D.A., and MacGillivray, I. The classification and definition of the hypertensive disorders of pregnancy. *Amer J Obstet Gynecol* 1988; 158(4):892.

27. Diamond, M.P., Entman, S.S., Slayer, S.L., Vaughn, W.K., and Boehm, F.H. Increased risk of endometritis and wound infection after Cesarean section in insulin-dependent diabetic women. *Amer J Obstet Gynecol* 1986; 155(2):297.
28. Dische, M.R., Quinn, P.A., Czegledy-Nagy, E., and Sturgess, J.M. Genital mycoplasma infection - Intrauterine infection: Pathologic study of the fetus and placenta. *Amer J Clin Pathol* 1979; 72(2):167.
29. Eickhoff, T.C., Klien, J.O., Daly, A.K., Ingall, D., and Finland M. Neonatal sepsis and other infections due to Group B beta-hemolytic Streptococci. *New Engl J Med* 1964; 71(24):1221.
30. Embil, J.A., Martin, T.R., Hansen, N.H., MacDonald, S.W., and Manuel, F.R. Group B beta hemolytic Streptococci in the female genital tract: A study of four clinic populations. *Brit J Obstet Gynaecol* 1978; 85:783.
31. Embree, J.E., Krause, V.W., Embil, J.A., and MacDonald, S. Placental infection with Mycoplasma hominis and Ureaplasma urealyticum: Clinical correlation. *Obstet Gynecol* 1980; 56(4):475.
32. Eschenbach, D.A., Buchanan, T.M., Pollock, H.M., Forsyth, P.S., Alexander, E.R., Lin, J., Wang, S., Wentworth, B.B., McCormack, W.M., and Holmes, K.K. Polymicrobial etiology of acute pelvic inflammatory disease. *New Engl J Med* 1975; 298(4):166.
33. Ford, D.K. Relationships between mycoplasma and the etiology of nongonococcal urethritis and Reiter's syndrome. *Ann New Yory Acad Sci* 1967; 143:501.
34. Ford, D.K., and MacDonald, J. Influence of urea on the growth of T-strain mycoplasmas. *J Bacteriol* 1967; 93(5):1509.
35. Fowlkes, D.M., Doohar, G.B., and O'Leary, W.M. Evidence by scanning electron microscopy for an association between spermatozoa and T-mycoplasmas in men of infertile marriage. *Fertil Steril* 1975; 26(12):1203.
36. Fowlkes, D.M., MacLeod, J., and O'Leary, W.M. T-mycoplasmas and human infertility: Correlation of infection with alterations in seminal parameters. *Fertil Steril* 1975; 26(12):1212.
37. Foulon, W., Naessens, A., Dewaele, M., Lauwers, S., and Amy, J.J. Chronic Ureaplasma urealyticum amnionitis associated with abruptio placentae. *Obstet Gynecol* 1986; 68(2):280.
38. Foy, H., Kenny, G., Bor, E., Hammar, S., Hickman, R. Prevalence of Mycoplasma hominis and Ureaplasma urealyticum (T strains) in urine of adolescents. *J Clin Microbiol* 1975; 2(3):226.
39. Frusca, T., Morassi, L., Pecorelli, S., Grigolato, P., and Gastaldi, A. Histologic features of uteroplacental vessels in normal and hypertensive patients in relation to birthweight. *Brit J Obstet Gynaecol* 1989; 96:835.
40. Garland, S.M., and Murton, L.J. Neonatal meningitis caused by Ureaplasma urealyticum. *Pediatr Infect Dis J* 1987; 6(9):868.

41. Gibbs, R.S., Blanco, J.D., St. Clair, P.J., and Castaneda, Y.S. Mycoplasma hominis and intrauterine infection in late pregnancy. *Sex Trans Dis* 1983; 10(4):303.
42. Gibbs, R.S., Cassell, G.H., Davis, J.K., and St. Clair, P.J. Further studies on genital mycoplasmas in intra-amniotic infection: Blood cultures and serologic response. *Amer J Obstet Gynecol* 1986; 154:717.
43. Gilbert, G.L., Garland, S.M., Fairley, K.F., and McDowall, D.M.R. Bacteriuria due to ureaplasmas and other fastidious organisms during pregnancy: Prevalence and significance. *Pediatr Infect Dis* 1986; 5(6):S239.
44. Gnärpe, H., and Friberg, J. Mycoplasma and human reproductive failure: I. The occurrence of different mycoplasmas in couples with reproductive failure. *Amer J Obstet Gynecol* 1972; 114:727.
45. Graber, C.D., Creticos, P., Valicenti, J., and Williamson, H.O. T-mycoplasma in human reproductive failure. *Obstet Gynecol* 1979; 54(5):558.
46. Gump, D.W., Gibson, M., and Ashikaga, T. Lack of association between genital mycoplasmas and infertility. *New Engl J Med* 1984; 310(15):937.
47. Hammerschlag, M.R., Alpert, S., Rosner, I., Thurston, P., Semine, D., McComb, D., and McCormack, W.M. Microbiology of the vagina in children: Normal and potentially pathogenic organisms. *Pediatrics* 1978; 62(1):57.
48. Hardy, P.H., Hardy, J.B., Nell, E.E., Graham, D.A., Spence, M.R., and Rosenbaum, R.C. Prevalence of six sexually transmitted disease agents among pregnant inner-city adolescents and pregnancy outcome. *Lancet* 1984; 2:333.
49. Harrison R.H. Cervical colonization with Ureaplasma urealyticum and pregnancy outcome: Prospective studies. *Pediatr Infect Dis* 1986; 5(6):S266.
50. Harrison, R.F., Hurley, R., and deLouvois, J. Genital mycoplasmas and birth weight in offspring of primigravid women. *Amer J Obstet Gynecol* 1979; 133:201.
51. Henry-Suchet, J., Catalan, F., Loffredo, V., Serfaty, D., Siboulet, A., Perol, Y., Sanson, M.J., Debache, C., Pigeau, F., Coppin, R., deBrux, J., and Poynard, T. Microbiology of specimens obtained by laparoscopy from controls and from patients with pelvic inflammatory disease or infertility with tubal obstruction: Chlamydia trachomatis and Ureaplasma urealyticum. *Amer J Obstet Gynecol* 1980; 138(7 pt 2):1022.
52. Hewish, M.J., Birch, D.F., and Fairley, K.F. Ureaplasma urealyticum serotypes in urinary tract disease. *J Clin Microbiol* 1986; 23(1):149.
53. Hillier S.L., Martius, J., Krohn, M., Kiviat, N., Holmes, K.K., and Eischenbach, D.A. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. *New Engl J Med* 1988; 319:972.
54. Holmes, M.J., Furr, P.M., and Taylor-Robinson, D. The persistence of mycoplasmas in the urogenital tract of men in the Antarctic. *J Hyg (Camb)* 1974; 72:355.
55. Horne, H.W., Hertig, A.T., Kundsinn, R.B., and Kosasa, T.S. Sub-clinical endometrial inflammation and T-mycoplasma - A possible cause of human reproductive failure. *Int J Fertil* 1973; 18:226.

56. Idress, W.M., Patton, W.C., and Taymor, M.L. On the etiologic role of Ureaplasma urealyticum (T-mycoplasma) infection in infertility. *Fertil Steril* 1978; 30(3):293.
57. Iwasaka, T., Wada, T., Kidera, Y., and Sugimori, H. Hormonal status and mycoplasma colonization in the female genital tract. *Obstet Gynecol* 1986; 68(2):263.
58. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The 1984 report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. *Arch Intern Med* 1984; 144(5):1045.
59. Kambam, J.R., Entman, S., Mouton, S., and Smith, B.E. Effect of preeclampsia on carboxyhemoglobin levels: A mechanism for a decrease in P₅₀. *Anesth* 1988; 68(3):433.
60. Kambam, J.R., Handte, R.E., Brown, W.U., and Smith, B.E. Effect of normal and pre-eclamptic pregnancies on the oxyhemoglobin dissociation curve. *Anesth* 1986; 65(4):426.
61. Kass, E.H., McCormack, W.M., Lin, J., Rosner, B., and Munoz, A. Genital mycoplasmas as a cause of excess premature delivery. *Trans Assoc Amer Phys* 1981; 94:261.
62. Kass, E.H., Lin, J.S., and McCormack, W.M. Low birth weight and maternal colonization with genital mycoplasmas. *Pediatr Infect Dis* 1986; 5(6):S279.
63. Khong, T.Y., De Wolf, F., Robertson, W.B., and Brosens, I. Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational age infants. *Brit J Obstet Gynaecol* 1986; 93:1049.
64. Klein, L.O., Buckland, D., and Finland, M. Colonization of newborn infants by mycoplasmas. *New Engl J Med* 1969; 280(19):1025.
65. Kundsins, R.B., and Driscoll, S.G. The role of mycoplasmas in human reproductive failure. *Ann New York Acad Sci* 1970; 174:794.
66. Kundsins, R.B., Driscoll, S.G., and Ming, P.L. Strain of mycoplasma associated with human reproductive failure. *Science* 1967; 157:1573.
67. Kundsins, R.B., Driscoll, S.G., Monson, R.R., Yeh, C., Bianco, S.A., and Cochran, W.D. Association of Ureaplasma urealyticum in the placenta with perinatal morbidity and mortality. *New Engl J Med* 1984; 310(15):941.
68. Leiberman, J.R., Meizner, I., Mazor, M., and Insler, V. Blood supply to the uterus in preeclampsia. *Eur J Obstet Gynecol Reprod Biol* 1988; 28:23.
69. Lewin, E.B., and Amstey, M.S. Natural history of group B Streptococcus colonization and its therapy during pregnancy. *Amer J Obstet Gynecol* 1981; 139(5):512.
70. Liepmann, M.F., Wattre, P., Dewilde, A., Papierok, G., and Delecour, M. Detection of antibodies to Ureaplasma urealyticum in pregnant women by enzyme-linked immunosorbent assay using membrane antigen and investigation of the significance of the antibodies. *J Clin Microbiol* 1988; 26(10):2157.

71. Likitnukul, S., Kusmiesz, H., Nelson, J.D., and McCracken, G.H. Role of genital mycoplasmas in young infants with suspected sepsis. *J Pediatr* 1986; 109(6):971.
72. Lin, J.L. Human mycoplasmal infections: Serologic observations. *Rev Infect Dis* 1985; 7(2):216.
73. Lin, J.L., and Kass, E.H. Fourteen serotypes of Ureaplasma urealyticum (T-mycoplasmas) demonstrated by the complement-dependent mycoplasmacidal test. *Infection* 1980; 8(4):152.
74. Lin, J.L., Kendrick, M.I., and Kass, E.H. Serologic typing of human genital T-mycoplasmas by a complement-dependent mycoplasmacidal test. *J Infect Dis* 1972; 126(6):658.
75. Mårdh, P., and Weström, L. Tubal and cervical cultures in acute salpingitis with special reference to Mycoplasma hominis and T-strain mycoplasmas. *Brit J Vener Dis* 1970; 46:179.
76. Matorras, R., García-Perea, A., Usandizaga, J.A., and Omeñaca, F. Recto-vaginal colonization and urinary tract infection by Group B Streptococcus in the pregnant diabetic patient. *Acta Obstet Gynecol Scand* 1988; 67:617.
77. McClure Brown, J.C., and Veall, N. The maternal placental blood flow in normotensive and hypertensive women. *J Obstet Gynaecol Brit Emp* 1953; 60(2):141.
78. McCormack, W.M. Ureaplasma urealyticum: Ecologic niche and epidemiologic considerations. *Pediatr Infect Dis* 1986; 5(6):S232.
79. McCormack, W.M., Almeida, P.C., Bailey, P.E., Grady, E.M., and Lee, Y. Sexual activity and vaginal colonization with genital mycoplasmas. *JAMA* 1972; 221(12):1375.
80. McCormack, W.M., Rosner, B., Alpert, S., Evrard, J.R., Crockett, V.A., and Zinner, S.H. Vaginal colonization with Mycoplasma hominis and Ureaplasma urealyticum. *Sex Trans Dis* 1986; 13(2):67.
81. McCormack, W.M., Rosner, B., and Lee, Y. Colonization with genital mycoplasmas in women. *Amer J Epidemiol* 1973; 97(4):240.
82. McCormack, W.M., Rosner, B., Lee, Y.H., Rankin, J.S., and Lin, J.L. Isolation of genital mycoplasmas from blood obtained shortly after vaginal delivery. *Lancet* 1975; 1:596.
83. McCormack, W.M., Lee, Y., and Zinner, S.H. Sexual experience and urethral colonization with genital mycoplasmas. A study in normal men. *Ann Internal Med* 1973; 78(5):696.
84. McDonald, M.I., Lam, M.H., Birch, D.F., D'arcy, A.F., Fairley, K.F., and Pavillard, E.R.J. Ureaplasma urealyticum in patients with acute symptoms of urinary tract infection. *J Urol* 1982; 128:517.
85. Morris, N., Osborn, S.B., and Wright, H.P. Effective circulation of the uterine wall in late pregnancy measured with ²⁴NaCl. *Lancet* 1955; 1:323.

86. Musci, T.J., Roberts, J.M., Rogers, G.M., and Taylor, R.N. Mitogenic activity is increased in the sera of preeclamptic women before delivery. *Amer J Obstet Gynecol* 1988; 159(6):1446.
87. Naessens, A., Foulon, W., Breynaert, J., and Lauwers, S. Serotypes of Ureaplasma urealyticum isolated from normal pregnant women and patients with pregnancy complications. *J Clin Microbiol* 1988; 26(2):319.
88. Naey, R.L. Pregnancy hypertension, placental evidences of low uteroplacental blood flow, and spontaneous premature delivery. *Human Pathol* 1989; 20(12):1039.
89. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 1979; 28(12):1039.
90. Pankuch, G.A., Appelbaum, P.C., Lorenz, R.P., Botti, J.J., Schechter, J., and Naeye, R. L. Placental microbiology and histology and the pathogenesis of chorioamnionitis. *Obstet Gynecol* 1984; 64(6):802.
91. Pecters, M.F., Polak-Vogelzang, A.A., Debruyne, F.M.J., and Van Der Veen, J. Role of mycoplasma in chronic prostatitis. *Yale J Biol Med* 1983; 56:551.
92. Piot, P. Distribution of eight serotypes of Ureaplasma urealyticum in cases of non-gonococcal urethritis and of gonorrhea, and in healthy persons. *Brit J Vener Dis* 1976; 52:266.
93. Polk, B.F., Berlin, L., Kanchanaraksa, S., et al. Association of Chlamydia trachomatis and Mycoplasma hominis with intrauterine growth retardation and preterm delivery. *Amer J Epidemiol* 1989; 129(6):1247.
94. Quinn, P.A., Arshoff, L.U., and Li, H.C.S. Serotyping of Ureaplasma urealyticum by immunoperoxidase assay. *J Clin Microbiol* 1981; 13(4):670.
95. Quinn, P.A., Butany, J., Chipman, M., Taylor, J., and Hannah, W. A prospective study of microbial infections in stillbirths and early neonatal death. *Amer J Obstet Gynecol* 1985; 151:238.
96. Quinn, P.A., Butany, J., Taylor, J., and Hannah, W. Chorioamnionitis: Its association with pregnancy outcome and microbial infection. *Amer J Obstet Gynecol* 1987; 156:379.
97. Quinn, P.A., Gillan, J.E., Markestad, T., St. John, M.A., Daneman, A., Lie, K.I., Li, H.C.S., Czegledy-Nagy, E., and Klein, M. Intrauterine infection with Ureaplasma urealyticum as a cause of fatal neonatal pneumonia. *Pediatr Infect Dis* 1985; 4(5):538.
98. Quinn, P.A., Rubin, S., Li, H.C.S., Nocilla, D.M., Read, S.E., and Chipman, M. Serological evidence of Ureaplasma urealyticum infection in neonatal respiratory disease. *Yale J Biol Med* 1983; 56:565.
99. Quinn, P.A., Shewchuk, A.B., Shuber, J., Lie, K.I., Ryan, E., Sheu, M., and Chipman, M.L. Serologic evidence of Ureaplasma urealyticum infection in women with spontaneous pregnancy loss. *Amer J Obstet Gynecol* 1983; 145:245.


100. Rehewy, M.S.E., Jaszczak, S., Hafez, E.S.E., Thomas, A., and Brown, W.J. Ureaplasma urealyticum (T-mycoplasma) in vaginal fluid and cervical mucus from fertile and infertile women. *Fertil Steril* 1978; 30(3):297.
101. Robertson, J.A., Honore, L.H., and Stemke, G.W. Serotypes of Ureaplasma urealyticum in spontaneous abortion. *Pediatr Infect Dis* 1986; 5(6):S270.
102. Robertson, J.A., and Stemke, G.W. Modified metabolic inhibition test for serotyping strains of Ureaplasma urealyticum (T-strain mycoplasma). *J Clin Microbiol* 1979; 9(6):673.
103. Robertson, J.A., and Stemke, G.W. Expanded serotyping scheme for Ureaplasma urealyticum strains isolated from humans. *J Clin Microbiol* 1982; 15(5):873.
104. Robinson, J., Canavan, J.P., El Haj, A.J., and Goldspink, D.F. Maternal diabetes in rats. I. Effects on placental growth and protein turnover. *Diabetes* 1988; 37:1665.
105. Rogers, G.M, Taylor, R.N., and Roberts, J.M. Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. *Amer J Obstet Gynecol* 1988; 159(4):908.
106. Romano, N., Romano, F., and Carollo, F. T-strains of mycoplasma in bronchopneumonic lungs of an aborted fetus. *New Engl J Med* 1971; 285(17):950.
107. Rudd, P.T., and Carrington, D. A prospective study of chlamydial, mycoplasmal and viral infections in a neonatal intensive care unit. *Arch Dis Child* 1984; 59:120.
108. Salata, R.A., Lerner, P.I., Shlaes, D.M., Gopalakrishna, K.V., and Wolinsky, E. Infections due to Lancefield Group C Streptococci. *Medicine* 1989; 68(4):225.
109. Sánchez, P.J., and Regan, J.A. Ureaplasma urealyticum colonization and chronic lung disease in low birth weight infants. *Pediatr Infect Dis* 1988; 7(8):542.
110. Savige, J., Gilbert, G.L., Fairley, K.F., and McDowall, D.R. Bacteriuria due to Ureaplasma urealyticum and Gardnerella vaginalis in women with preeclampsia. *J Infect Dis* 1983; 148(3):605.
111. Shaw, N.J., Pratt, B.C., and Weindling, A.M. Ureaplasma and Mycoplasma infections of the central nervous system in preterm infants. *Lancet* 1989; 2:1530.
112. Shepard, M.C. The recovery of pleuropneumonia-like organisms from Negro men with and without non-gonococcal urethritis. *Amer J Syph Gonorr Ven Dis* 1954; 38:113.
113. Shepard, M.C., and Lunceford, C.D. Occurrence of urease in T strains of Mycoplasma. *J Bacteriol* 1967; 93(5):1513.
114. Shepard, M.C., and Lunceford, C.D. Serologic typing of Ureaplasma urealyticum isolates from urethritis patients by an agar growth inhibition method. *J Clin Microbiol* 1978; 8(5):566.
115. Shepard, M.C., Lunceford, C.D., Ford, D.K., Purcell, R.H., Taylor-Robinson, D., Razin, S., and Black, F.T. Ureaplasma urealyticum gen. nov., sp. nov.: Proposed nomenclature for the human T (T-strain) Mycoplasmas. *Int J Syst Bacteriol* 1974; 24(2):160.

116. Sheppard, B.L., and Bonnar, J. An ultrastructural study of the utero-placental spiral arteries in hypertensive and normotensive pregnancy and fetal growth retardation. *Brit J Obstet Gynaecol* 1981; 88:695.
117. Sompolinsky, D., Solomon, F., Elkina, L., Weinraub, Z., Bukovsky, I., and Caspi, E. Infection with mycoplasma and bacteria in induced midtrimester abortion and fetal loss. *Amer J Obstet Gynecol* 1975; 121(5):610.
118. Stagno, S., Brasfield, D.M., Brown, M.B., Cassell, G.H., Pifer, L.L., Whitley, R.J., and Tiller, R.E. Infant pneumonitis associated with Cytomegalovirus, Chlamydia, Pneumocystis, and Ureaplasma: A prospective study. *Pediatrics* 1981; 68(3):322.
119. Stemke, G.W., and Robertson J.A. Problems associated with serotyping strains of Ureaplasma urealyticum. *Diagn Microbiol Infect Dis* 1985; 3:311.
120. Stray-Pedersen, B., Eng, J., and Reikvam, T.M. Uterine T-mycoplasma colonization in reproductive failure. *Amer J Obstet Gynecol* 1978; 130:307.
121. Stuckey, M., Quinn, P.A., and Gelfand, E.W. Identification of Ureaplasma urealyticum (T-strain mycoplasma) in a patient with polyarthritis. *Lancet* 1978; 2:917.
122. Sweet, R.L. Colonization of the endometrium and fallopian tubes with Ureaplasma urealyticum. *Pediatr Infect Dis* 1986; 5(6):S244.
123. Sweet, R.L., Draper, D.L., Schechter, J., James, J., Hadley, W.K., and Brooks, G.F. Microbiology and pathogenesis of acute salpingitis as determined by laparoscopy: What is the appropriate site to sample? *Amer J Obstet Gynecol* 1980; 138(7 pt 2):985.
124. Tafari, N., Ross, S., Naeye, R.L., Judge, D.M., and Marboe, C. Mycoplasma T-strains and perinatal death. *Lancet* 1976; 1:108.
125. Taylor-Robinson, D., and Gourlay, R.N. Ureaplasma. In Kreig and Holt (Editors), Bergey's Manual of Systematic Bacteriology. Vol. 1. Williams and Wilkins, Baltimore. 1984. pp 770-775.
126. Tulley, J.G., and Taylor-Robinson, D. Taxonomy and host distribution of the ureaplasmas. *Pediatr Infect Dis* 1986; 5(6):S292.
127. Tulley, J.G., Taylor-Robinson, D., Rose, D.L., Furr, P.M., and Hawkins, D.A., Evaluation of culture media for the recovery of Mycoplasma hominis from the human urogenital tract. *SEX TRANS DIS*. 1983. 10(4): 256-260.
128. Tulley, J.G., Whitcomb, R.F., Clark, H.F., and Williamson, D.L. Pathogenic mycoplasmas: Cultivation and vertebrate pathogenicity of a new spiroplasma. *Science* 1977; 195(3):892.
129. Turunen, H., Leinikki, P., and Jansson, E. Serological characterization of Ureaplasma urealyticum strains by enzyme-linked immunosorbent assay (ELISA). *J Clin Path* 1982; 35:439.
130. Vartain, C., Lerner, P.I., Shales, D.M. and Gopalakrishna, K.V. Infections due to Lancefield group G Streptococci. *Medicine* 1985; 64(2):75.

131. Vogler, L.B., Waites, K.B., Wright, P.F., Perrin, J.M., and Cassell, G.H. Ureaplasma urealyticum polyarthritis in agammaglobinemia. *Pediatr Infect Dis* 1985; 4(6):687.
132. Viarengo, J., Hebrant, F., and Piot, P. Ureaplasma urealyticum in the urethra of healthy men. *Brit J Vener Dis* 1980; 56:169.
133. Wang, E.E.L., Frayha, H., Watts, J., Hammerberg, O., Chernesky, M.A., Mahony, J.B., and Cassell, G.H. Role of Ureaplasma urealyticum and other pathogens in the development of chronic lung disease of prematurity. *Pediatr Infect Dis* 1988; 7(8):547.
134. Waites, K.B., Crouse, D.T., Phillips, J.B., Canupp, K.C., and Cassell, G.H. Ureaplasma pneumonia and sepsis associated with persistent pulmonary hypertension of the newborn. *Pediatrics* 1989; 83(1):79.
135. Waites, K.B., Rudd, P.T., Crouse, D.T., Canupp, K.C., Nelson, K.G., Ramsey, C., and Cassell, G.H. Chronic Ureaplasma urealyticum and Mycoplasma hominis infections of central nervous system in preterm infants. *Lancet* 1988; 1:17.
136. Webster, A.D.B., Taylor-Robinson, D., Furr, P.M., and Asherson, G.L. Mycoplasma (ureaplasma) septic arthritis in hypogammaglobulinaemia. *Brit Med J* 1978; 1:478.
137. White, P. Classification of obstetric diabetes. *Amer J Obstet Gynecol* 1978; 130(2):228.
138. World Health Organization. Diabetes mellitus: Report of a WHO Study Group. *WHO Tech Rep Ser* 1985; 727:1.


APPENDIX 1
POWER CURVES

Power Calculations All Diabetes




N = 573

Power Calculations All Chronic Hypertension




N = 573

Power Calculations All Pregnancy Induced Hypertension



N = 573

Power Calculations All Hypertension (CHT or PIH)



APPENDIX 2
OBAR DATA SHEETS

PRENATAL HISTORY

OBAR NO. _____ CHART NO. _____ INTERVIEWER: _____

 NAME: _____ CLINIC: _____ DATE: _____
 Last First (M)

Birthdate			Age		Race (circle)		Marital Status (circle)		Address		Medicaid No.	
Mo	Day	Yr	W	B	O	S	M	W	D	Zip	Phone:	
Plans to Deliver:			Occupation:		If outside work type		Last Grade Completed		Emergency Contact		Relationship Phone	
			Homemaker									
			Outside work									
			Student									

FAMILY HISTORY	Code:	F—Father	PGP—Paternal Grandparent	S—Sibling	O—Neg +—Pos	Comments:
		M—Mother	MGP—Maternal Grandparent	O—Negative		
	Hypertension	TB	DES		Plans to breast feed?	
	Heart Disease	Epilepsy	Multi Births		Desires T.L.?	
	Diabetes	Allergies—Asthma	Comments		Preg. Planned?	
Genetic Screening: Neg Hx _____ Pos Hx _____ If Pos Hx, mark (+) appropriate indications below:						
	Down's Syndrome (mongolism)	Hydrocephalus	Cystic Fibrosis	Mental Retardation		
	Spina Bifida	Hemophilia	A stillborn	Other inherited disorders		
	Meningocele	Muscular Dystrophy	Birth Defect(s)	Comments:		

PAST MEDICAL HISTORY	History	O-Neg +—Pos	Detail Pos./Remarks Include date & Type of Rx	History	O-Neg +—Pos	Detail Pos./Remarks Include date & Type of Rx
	Diabetes			Drug Sensitivity (Specify & mark chart)		
	Hypertension			Blood Dyscrasia (Anemia)		
	Heart Disease			Blood Transfusion		
	Kidney Disease			Rh ABO Sens		
	Tuberculosis			Allergies—Asthma		
	Rheumatic Fever			Operations—Year & Reas		
	Thyroid Dysfunction			Accidents		
	Epilepsy			Nervous & Mental		
	Varicoseities			GYN Disorder		
	Phlebitis			German Measles		
	Herpes			Venereal Disease		
	Hepatitis B					
	Use of Narcotics					
	Use of Tobacco		# cigs/day prior to preg _____	# cigs/day now _____	Age onset Smoking _____ Yr:	
Use of Alcohol		# drinks/wk prior to preg _____	# drinks/wk now _____	Age onset drinking _____ Yr:		

OBSTETRICAL HISTORY—THIS PREGNANCY	History	O-Neg +—Pos	Detail Pos./Remarks Include date & Type of Rx	History	O-Neg +—Pos	Detail Pos./Remarks Include date & Type of Rx
	Bleeding			Edema		
	Vaginal Discharge			Abdominal Pain		
	Nausea			Urinary Complaints		
	Vomiting			German Measles		
	Indigestion			Other Viral Illnesses		
	Constipation			Radiation specify		
	Diarrhea			Accident		
	Headache			Medications		
	Initial Prenatal Visit Site _____			Trimester at last prenatal visit _____		
	Site Codes:			0—First 2—Third		
	00—BHC 05—Faculty 10—Non-Jeffco MD Clin 20—Other			1—Second 3—Unknown		
	01—CNC 06—Comp Clin 11—Non-Jeffco Pst MD					
	02—EHC 07—THC 12—Jeffco Pst MD					
	03—MHC 08—CGH 13—UAB Family Practice					
04—WHC 09—UAH 14—Save a Life Campaign						
Comments						

PRENATAL PHYSICAL EXAMINATION

OBAR NO _____

CHART NO _____

NAME _____ AGE _____ CLINIC _____

Full Term	Prem.	Abort.	Live	Mult. Births	Menstrual Periods: Onset	LMP: <input type="checkbox"/> Known / / <input type="checkbox"/> Approximate (Month known, day uncertain) <input type="checkbox"/> Unknown (Month & day unknown)	If day of LMP is uncertain, was it the: <input type="checkbox"/> First of the month? <input type="checkbox"/> Middle of the month? <input type="checkbox"/> End of the month?
-----------	-------	--------	------	--------------	--------------------------	--	--

 Age - Yrs _____ Was the LMP normal in timing, amount, duration? ☐ No ☐ Yes

PAST PREGNANCIES	Last Ten	Date Mo/Yr	Preg Abort E/S/T	Born A/D	GA Wks.	Weight Lbs/Ozs	Type Del. V/C	Labor (Hours)	Place Deliv	How A/D	Comments / Complications

 PELVIC EXAM: ☐ Not Examined ☐ Examined DATE OF EXAM: ____/____/____

Systems	Normal <input type="checkbox"/>	Selected Abnormalities <input type="checkbox"/>				Other <input type="checkbox"/>	Detail All Poss
1 Skin		<input type="checkbox"/> Rashes	<input type="checkbox"/> Eruptions	<input type="checkbox"/> Pallor	<input type="checkbox"/> Jaundice		
2 Eyes		<input type="checkbox"/> Lid Lag	<input type="checkbox"/> Unequal Pupils	<input type="checkbox"/> Light Reflex	<input type="checkbox"/> Light Reflex		
3 ENT		<input type="checkbox"/> Abn. Mucosa	<input type="checkbox"/> Exudates	<input type="checkbox"/> Inflammation	<input type="checkbox"/> Hearing Loss		
4 Mouth/Teeth		<input type="checkbox"/> Canines	<input type="checkbox"/> Gingivitis	<input type="checkbox"/> Sores	<input type="checkbox"/> Dentures		
5 Neck/Thyroid		<input type="checkbox"/> Asymmetry	<input type="checkbox"/> Adenopathy	<input type="checkbox"/> Enlarged Thy	<input type="checkbox"/> Pulsations		
6 Chest		<input type="checkbox"/> Asymmetry	<input type="checkbox"/> > A-P Diam	<input type="checkbox"/> Rub	<input type="checkbox"/>		
7 Lungs		<input type="checkbox"/> < Sounds	<input type="checkbox"/> > Sounds	<input type="checkbox"/> Rales/Rhonchi	<input type="checkbox"/> Wheezing		
8 Breasts		<input type="checkbox"/> Asymmetry	<input type="checkbox"/> Mass/Node	<input type="checkbox"/> Discharge	<input type="checkbox"/> Tenderness		
9 Heart		<input type="checkbox"/> Abn. Size	<input type="checkbox"/> Arrhythmias	<input type="checkbox"/> Murmurs	<input type="checkbox"/> Sounds		
10 Abdomen		<input type="checkbox"/> Mass	<input type="checkbox"/> Hernia	<input type="checkbox"/> Obese	<input type="checkbox"/> Scars		
11 Extremities		<input type="checkbox"/> Vascosities	<input type="checkbox"/> Ulcerations	<input type="checkbox"/> Edema	<input type="checkbox"/> Deformations		
12 Reflexes		<input type="checkbox"/> Unequal	<input type="checkbox"/> Hypoactive	<input type="checkbox"/> Hyperactive	<input type="checkbox"/> Absent		
Pelvic Exam							
13 Vagina		<input type="checkbox"/> Vascosities	<input type="checkbox"/> Vulvitis	<input type="checkbox"/> Condyloma	<input type="checkbox"/> Lesions		
14 Perineum		<input type="checkbox"/> Old Lacerations	<input type="checkbox"/> Relaxed	<input type="checkbox"/> Surgical Scar	<input type="checkbox"/>		
15 Vagina		<input type="checkbox"/> Discharge	<input type="checkbox"/> Vascosities	<input type="checkbox"/> Cystocele	<input type="checkbox"/> Rectocele		
16 Cervix		<input type="checkbox"/> Open	<input type="checkbox"/> Inflamed	<input type="checkbox"/> Bleeding	<input type="checkbox"/> Lesions		
17 Adnexa (L)		<input type="checkbox"/> Not Palpable	<input type="checkbox"/> Thickened	<input type="checkbox"/> Tender	<input type="checkbox"/> Masses		
(R)		<input type="checkbox"/> Not Palpable	<input type="checkbox"/> Thickened	<input type="checkbox"/> Tender	<input type="checkbox"/> Masses		
18 Uterus		<input type="checkbox"/> Sm. for Dates	<input type="checkbox"/> Lig. for Dates	<input type="checkbox"/> Fibroids	<input type="checkbox"/>		
19 Rectum		<input type="checkbox"/> Int. Hemorrhoids	<input type="checkbox"/> Ext. Hemorrhoids/Mass	<input type="checkbox"/>	<input type="checkbox"/>		

Pelvimetry	Arch	Coxyx	Sacrum	Sacral Spine	Adequate	Borderline	Contracted	Prognosis for Delivery
Diagonal Conj _____ cm	<input type="checkbox"/> Normal	<input type="checkbox"/> Mobile	<input type="checkbox"/> Concave	<input type="checkbox"/> Average	Inlet			Good _____ Fair _____
Prom. Reached? _____ N/A	<input type="checkbox"/> Wide	<input type="checkbox"/> Forward	<input type="checkbox"/> Straight	<input type="checkbox"/> Prominent	Mid Pelvis			
Trans Diam Out _____ cm	<input type="checkbox"/> Narrow	<input type="checkbox"/> Fligid	<input type="checkbox"/> Convex	<input type="checkbox"/> Blunt	Outlet			Signed _____

Pelvic Exam end/or Comments

Progress Notes

PS-1002

PRENATAL SUBSEQUENT VISITS

OBBARNO		CHART NO.		Third Trimester Risks	
				Rh Negative _____	
NAMIE _____				Previous C/S _____	
				AS-AC _____	
				UTI _____	
				Herpes _____	
AGE _____	HGT _____ cm	CLINIC _____			

FETUS							
Visit Date (yr. ____)	____						
Weeks Gest Best Est	____						
Mt Fundus (cm)	____						
Presentation - VTX BR Trans	____						
FHT Present	1 2						
Quadrant	3 4						
Or O - Absent	____						
Fetal Movement P-present D-decreased	____						
A-absent	____						
Ss	Edema						
--Present	Bleeding						
O-Absent	Discharge						
	Dysuria						
	Other						
Blood Pressure	____	/	/	/	/	/	/
Recheck Blood Pressure	____	/	/	/	/	/	/
WL Kg (Non-Pregnant wt) _____	Kgs }						
Nutrition Code	____						
Date WIC Certified _____	/ /						
Routine - Therapeutic R/T	____						
HGB or HCT	____						
URINE	Sugar (0/4+)						
	Albumin (0/4+)						
	Testuria CC (0/-)						
	Testuria MC (0/-)						
	Number of Colonies						
	Ketones						
For Rh neg - Annuody Scr initially & @ 23, 28, 32, 36 wks	____						
Rhogam Date	____						
Tests	VDRL - Neg / Pos						
	GC - Neg / Pos						
	Diabetic Screen - Numeric Value						
	GTI - Neg / Pos / Eqv						
	Urine Culture - Neg / Pos / Eqv						
Date Sonar Performed	____						
BPD (wks)	____						
FL (wks)	____						
Placental Location Fun/Ant/L/Poss/Prev	____						
Next Appointment Date	____						
Site of Next Visit	____						
Rn Name (Initials & Last Name)	____						
MD Name (Initials & Last Name)	____						

TEST	Blood/Rh Type	HGB Screen	HI Titer	UCG	Rubella Screen	Mant Test	Pap Smear
Date	____	____	____	____	____	____	____
Results	A B AB O + -	AA AS SS AC SC AF	-	-	Immune/Not Immune	Itz *	

EDC Computations From	LMP	_____	_____
Initial Exam	_____ wks on	_____	_____
Fetal Heart First Heard on	_____	_____	_____
Quickening Noted on	_____	_____	_____

Working EDC _____
(Revised) _____

NAME: _____

RECORD #: _____

ROUTINE PRENATAL LAB

	<u>ITEM</u>	<u>DATE</u>	<u>RESULT</u>	<u>NOTED BY</u>	<u>PROBLEM</u>
<u>Initial Visit</u>	Rh type	_____	_____	_____	_____
	Ab screen	_____	_____	_____	_____
	Pap smear	_____	_____	_____	_____
	VDRL	_____	_____	_____	_____
	GC	_____	_____	_____	_____
	PCV	_____	_____	_____	_____
	Urine C&S	_____	_____	_____	_____
	III titer	_____	_____	_____	_____
	S-Hgb Screen	_____	_____	_____	_____
	Hepatitis B surf. antigen	_____	_____	_____	_____
<u>16 weeks</u>	MSAFP	_____	_____	_____	_____
<u>24-28 weeks</u>	50gm Glucola screen FBS	_____	_____	_____	_____
	1 Hr.	_____	_____	_____	_____
	PCV	_____	_____	_____	_____
<u>28 weeks</u>	RhoGam (if indicated)	_____	_____	_____	_____
<u>36 weeks</u>	PCV	_____	_____	_____	_____
	Repeat VDRL (if indicated)	_____	_____	_____	_____
	Repeat GC (if indicated)	_____	_____	_____	_____

NAME: _____

RECORD #: _____

SPECIAL PRENATAL LAB TESTS

	DATE: _____	RESULTS _____
Glucose Tolerance Test	_____	FBS _____
		1 hr. _____
		2 hr. _____
		3 hr. _____
Hemoglobin A _{1c}	_____	_____
ANA	_____	_____
Anticardiolipin	_____	_____
Lupus Anticoagulant (LAC)	_____	_____
Thyroid studies:		
T ₃ Resin Uptake	_____	_____
Total T ₄	_____	_____
TSH	_____	_____
Fetal karyotype, AF-AFP	_____	_____

24-hr. Urine

	Date: ____/____/____	Date: ____/____/____	Date: ____/____/____
Serum creatinine	_____	_____	_____
Urine Protein	_____	_____	_____
Creatinine clearance	_____	_____	_____

Other _____

the University of Alabama in Birmingham
the Medical Center / UNIVERSITY OF ALABAMA HOSPITALS

POST DELIVERY SUMMARY
MAJOR ANTEPARTUM DIAGNOSES
(CHECK ALL APPLICABLE)

PAGE 1 OF 4 PAGES

154. Fetal Referral
01 | None
1 | Yes

155. If Yes, When Referred
1 | During Labor
2 | Prior to Labor for Delivery
3 | For Antepartum Care

185. Referring MD _____
202. Hospital _____
223. County _____

160. Nutrition:
Weight Gain
01 | Normal (20-35 lbs)
1 | > 35 lbs
2 | < 20 lbs
3 | Unknown

161. CNS
01 | None
1 | Depression
2 | Psychosis
3 | Severe Disorder (What Drug?)
4 | Dysthymia/Depression
5 | Phencyclidine
6 | Other (Specify) 162
7 | Unknown

163. Heart Disease
01 | None
1 | Congenital Class 164
2 | Rheumatic
3 | Unknown

165. GI Disease
01 | None
1 | Appendicitis
2 | Cholecystitis
3 | Unknown
4 | Other (Specify) 166

167. Respiratory
01 | None
1 | Asthma
2 | Tuberculosis
3 | Pneumonia
4 | Unknown
5 | Other (Specify) 168

169. Urinary Tract Disease
01 | None
1 | Asymptomatic Bacteriuria
2 | Acute Cystitis
3 | Acute Pyelonephritis
4 | Other Acute (Specify) 170
5 | Chronic Pyelonephritis
6 | Other Chronic (Specify) 171

172. Hematology - Erythrocytosis
01 | None
1 | No Hcg without Seroconversion
2 | No Hcg Seroconverted without Amnio
3 | No Hcg Seroconverted with Amnio (See below)
4 | Δ OD Zone 1
5 | Δ OD Zone 2
6 | Δ OD Zone 3
Instructive Transfusion
7 | Yes x of Transfusions 173
8 | Seroconverted ABO Incompatibility
9 | Seroconverted Minor Blood Group

174. Other Hematology
01 | None
1 | Anemia (PCV < 30)
2 | Hemoglobinopathy (Type) 175 (Specify)
3 | Leukemia
4 | Other (Specify) 176

177. Coagulation
01 | None
1 | Thrombocytopenia
2 | Pulmonary Embolism
3 | Unknown
4 | Other (Specify) 178

179. Hypertension (Include Intrapartum)
01 | None
1 | Toxicosis (Acute)
2 | Chronic
3 | Chronic plus acute
4 | Unknown
Highest BP 180 / 181

182. If Hypertensive
01 | No Applicable
1 | Severe or Comp
2 | Proteinuria > 300 mg/day 183
3 | Creatinine Clearance < 100 ml/min
4 | Edema/plethoric Abnormality
5 | Coagulopathy
6 | Stroke
7 | None of Above
8 | Unknown
9 | Other (Specify) 184

186. Medications if Hypertensive
01 | No Applicable
1 | Name
2 | MgSO₄
3 | Phenytoin
4 | Methyldopa
5 | Hydralazine
6 | Other (Specify) 187

188. Endocrine
01 | None
1 | Hypothyroidism
2 | Hyperthyroidism
3 | Diabetes Mellitus (A & B) (Specify) 189
Highest Daily Insulin Requirement (HPI) = mg/l 190
4 | Unknown
5 | Other (Specify) 191

KEYPLATE

LMP: Mo Day Yr EDC: Mo Day Yr
Pregnancy Status: F P A L 151 152
153. GA (Weeks) (Best estimate)

192. Genital
01 | None
1 | Uterine Anomaly (Specify) 193
2 | Incompetent Cervix
3 | Unknown
4 | Other (Specify) 194

195. Other Infections
01 | None
1 | Parvovirus B19 Infection
2 | Breast Abscess
3 | Flu Syndrome
4 | Escherichia coli 51
5 | Peritonitis
6 | Rubella
7 | Strep
8 | Staph
9 | Herpes Virus Vaginitis
10 | Vaginitis (Specify) 196
11 | Monilia
12 | Trichomonas
13 | Non Specific
14 | Positive VDRL
15 | Unknown
16 | Other (Specify) 197

197. Fetal Condition From to Labor
01 | Normal
1 | Post Maturity (> 42 wks)
2 | IUGR
3 | Fetus Congenital Abnormal
4 | Fetus Multiple Gestation
5 | Fetus Fetal Distress
6 | Amniotic Fluid Shortage
7 | Positive OCT
8 | Unknown
9 | Other (Specify) 198

199. Lab Evidence of Maturity
01 | None
1 | 175 Ratio (Specify) 200
2 | Shake Test 204
3 | Positive
4 | Negative
5 | Unknown
6 | Other (Specify) 205

PS-1002

the University of Alabama in Birmingham
the Medical Center / UNIVERSITY OF ALABAMA HOSPITALS

PAGE 2 OF 4 PAGES



KEYPLATE

706 Cervix (On Admission)	
<input type="checkbox"/> Not Examined	<input checked="" type="checkbox"/> Examined
<input type="checkbox"/> Unknown	

	0	1	2	3
707 Dilatation (cm)	0	1-2	3-4	5
708 Effacement (%)	0-30	40-50	60-70	80
709 Station	-3	-2	-1	+1
710 Consistency	firm	med.	soft	
711 Position	anterior mid posterior			
Total Bishop Score	_____ = 212 _____			

713 Premature Labor (< 36 Weeks)	
<input type="checkbox"/> No	<input checked="" type="checkbox"/> Yes, No Attempts to Inhibit
<input type="checkbox"/> No	<input checked="" type="checkbox"/> Yes, Attempts to Inhibit (Check Below)
<input type="checkbox"/> Successful	<input checked="" type="checkbox"/> Failed
<input type="checkbox"/> Unknown	

714 Agents Used to Inhibit Labor	
<input type="checkbox"/> Alcohol	<input checked="" type="checkbox"/>
<input type="checkbox"/> Insulin	<input checked="" type="checkbox"/>
<input type="checkbox"/> Other _____	(Specify) _____ 215 _____

716 Labor	
<input type="checkbox"/> No Labor	<input checked="" type="checkbox"/>
<input type="checkbox"/> Spontaneous	<input checked="" type="checkbox"/>
<input type="checkbox"/> Induced	<input checked="" type="checkbox"/>
<input type="checkbox"/> Augmented	<input checked="" type="checkbox"/>

717 Labor	
Date of Onset _____	249 Date of Delivery _____
Time of Onset _____	158 Time at Delivery _____
(Use 24 hr clock) (Use 24 hr clock)	

Circle appropriate answer	0	1	2	3
218 Latent stage (< 1 cm/hr)	0-5	5-10	10-20	> 20
221 Active stage (> 1 cm/hr)	0-2	2-5	5-10	> 10
157 2nd stage	< 1	1-2	2-3	> 3
159 3rd stage	< 1 min	1-5 min	> 5 min	

723 Labor Curve (Check All Applicable)	
<input type="checkbox"/> Not Done	<input checked="" type="checkbox"/>
<input type="checkbox"/> Normal Labor Pattern	<input checked="" type="checkbox"/>
<input type="checkbox"/> Prolonged Latent Phase	> 20 hrs. Prostaglandin < 18 hrs. Oxytocin
<input type="checkbox"/> Primary and Secondary Arrest	< 10 cm (No Prostaglandin or Oxytocin) > 10 cm (With Prostaglandin or Oxytocin)
<input type="checkbox"/> Arrest of Descent (Frequency C/S or Forceps)	
<input type="checkbox"/> Arrest of Contractions (Prolonged 2nd Stage)	
<input type="checkbox"/> Arrest of Contractions (Frequency C/S or Forceps)	
<input type="checkbox"/> Prolonged 3rd Stage (> 30 Min.)	
<input type="checkbox"/> Failed Trial of Labor	
<input type="checkbox"/> Unknown	

Indications For Uterine Stimulant (Check All Applicable From Each Column)	
224 For Induction	225 For Augmentation
<input type="checkbox"/> Not Applicable	<input checked="" type="checkbox"/>
<input type="checkbox"/> Elective	<input checked="" type="checkbox"/>
<input type="checkbox"/> Abruptio Placentae	<input checked="" type="checkbox"/>
<input type="checkbox"/> Anemia	<input checked="" type="checkbox"/>
<input type="checkbox"/> Chronic Hypertension	<input checked="" type="checkbox"/>
<input type="checkbox"/> Tachycardia	<input checked="" type="checkbox"/>
<input type="checkbox"/> Diabetes Mellitus	<input checked="" type="checkbox"/>
<input type="checkbox"/> Erythroblastosis	<input checked="" type="checkbox"/>
<input type="checkbox"/> Positive OCT	<input checked="" type="checkbox"/>
<input type="checkbox"/> PROM	<input checked="" type="checkbox"/>
<input type="checkbox"/> Prolonged Pregnancy	<input checked="" type="checkbox"/>
<input type="checkbox"/> Hypotonic Contractions	<input checked="" type="checkbox"/>
<input type="checkbox"/> Poor Progress With Adequate Contractions	<input checked="" type="checkbox"/>
<input type="checkbox"/> Other _____	<input checked="" type="checkbox"/>
(Specify) _____	(Specify) _____
226 _____	227 _____

Primary Indication (Among Those Above) _____

Uterine Stimulant (Not For Placement)	
229 For Induction	230 For Augmentation
<input type="checkbox"/> None	<input checked="" type="checkbox"/>
<input type="checkbox"/> ARM	<input checked="" type="checkbox"/>
<input type="checkbox"/> Glyceryl	<input checked="" type="checkbox"/>
<input type="checkbox"/> Prostaglandin	<input checked="" type="checkbox"/>
<input type="checkbox"/> Spongy Membrane(s)	<input checked="" type="checkbox"/>
<input type="checkbox"/> Other _____	<input checked="" type="checkbox"/>
(Specify) _____	(Specify) _____
231 _____	232 _____

235 Reaction to Uterine Stimulant	
<input type="checkbox"/> Not Applicable	<input checked="" type="checkbox"/>
<input type="checkbox"/> No Unpleasant Effect	<input checked="" type="checkbox"/>
<input type="checkbox"/> No Uterine Response	<input checked="" type="checkbox"/>
<input type="checkbox"/> Sustained Contraction For _____ Min	
<input type="checkbox"/> Persistent Increased Uterine Tone	
<input type="checkbox"/> Unknown	
<input type="checkbox"/> Other Unusual Reaction _____	(Specify) _____ 233 _____

738 Diagnosis of CPD (Check All Applicable)	
<input type="checkbox"/> None	<input checked="" type="checkbox"/>
<input type="checkbox"/> By Arrest of Labor	<input checked="" type="checkbox"/>
<input type="checkbox"/> By Physical Exam	<input checked="" type="checkbox"/>
<input type="checkbox"/> By X-Ray Pelvimetry	<input checked="" type="checkbox"/>

739 X Ray Pelvimetry	
<input type="checkbox"/> None	<input checked="" type="checkbox"/>
240-241 Inlet	AP Trans
Mid-Pelvis	
242-243 Outlet	
244-245 Outlet	

746 Episiotomy	
<input type="checkbox"/> None	<input checked="" type="checkbox"/>
<input type="checkbox"/> Median	<input checked="" type="checkbox"/>
<input type="checkbox"/> Medio-Lateral	<input checked="" type="checkbox"/>

747 Lacerations (Regions)	
<input type="checkbox"/> None	<input checked="" type="checkbox"/>
<input type="checkbox"/> Vagina	<input checked="" type="checkbox"/>
<input type="checkbox"/> Perineal - 1st	<input checked="" type="checkbox"/>
<input type="checkbox"/> Perineal - 2nd	<input checked="" type="checkbox"/>
<input type="checkbox"/> Anal - 1st	<input checked="" type="checkbox"/>
<input type="checkbox"/> Anal - 2nd	<input checked="" type="checkbox"/>
<input type="checkbox"/> Other _____	(Specify) _____ 248 _____

750 Cause of Excessive Bleeding	
<input type="checkbox"/> No Excessive Bleeding	<input checked="" type="checkbox"/>
<input type="checkbox"/> Placenta Previa	<input checked="" type="checkbox"/>
<input type="checkbox"/> Placental Abruption	<input checked="" type="checkbox"/>
<input type="checkbox"/> Marginal Sinus Rupture	<input checked="" type="checkbox"/>

INFANT SHEET

PAGE 3 OF 4 PAGES

(FILL OUT ANOTHER SEPARATE SHEET FOR EACH INFANT)

<p>339. Infant's Hosp # _____</p> <p>257. This Birth</p> <p>1 Singleton</p> <p>2 Twin</p> <p>3 Triplet</p> <p>258. If Multiple Birth</p> <p>1 Child A (1st)</p> <p>2 Child B (2nd)</p> <p>3 Child C (3rd)</p>	<p>271. Fetal Monitor</p> <p>0 Not Done</p> <p>1 External</p> <p>2 Internal</p> <p>272. If Fetal Monitoring (Check All Applicable)</p> <p>0 Normal</p> <p>1 FHR Baseline < 120 BPM</p> <p>2 FHR Baseline > 160 BPM</p> <p>3 Decreased Beat-to-Beat Variability</p> <p>Variable Decelerations (Recurrent)</p> <p>4 Max. Decelerations < 30 BPM</p> <p>5 Max. Decelerations 30-50 BPM</p> <p>6 Max. Decelerations > 50 BPM</p> <p>Late Decelerations (Recurrent)</p> <p>7 Max. Decelerations < 10 BPM</p> <p>8 Max. Decelerations 10-30 BPM</p> <p>9 Max. Decelerations > 30 BPM</p> <p>Prolonged Decelerations</p> <p>10 > 2 Min.</p> <p>11 Other (Specify) _____ 273.</p>	<p>Rupture of Membranes</p> <p>280. Date of Rupture</p> <p>Mo : Day : Yr</p> <p>281. Time of Rupture</p> <p>_____</p> <p>(Use 24 Hr. Clock)</p> <p>282. Type of Rupture</p> <p>0 Spontaneous</p> <p>1 Artificial</p> <p>Duration of Rupture (To Nearest Hr.)</p> <p>283. Prior to Onset of Labor _____</p> <p>(Leave Blank if N.A.)</p> <p>284. Prior to Delivery _____</p> <p>(0 Means at Delivery)</p> <p>285. Reason for Amniotomy</p> <p>0 Not Performed</p> <p>1 Elective</p> <p>2 Terminal in DR or at C/S</p> <p>3 Induction of Labor</p> <p>4 Augmentation of Labor</p> <p>5 Monitor Fetus</p> <p>6 Unintentional</p> <p>7 Unknown</p> <p>8 Other (Specify) _____ 286.</p> <p>287. Amniotic Fluid</p> <p>0 Clear</p> <p>1 Meconium</p> <p>2 Bloody</p> <p>3 Unknown</p> <p>288. Amniotic Volume</p> <p>0 Normal</p> <p>1 Oligohydramnios</p> <p>2 Polyhydramnios</p> <p>3 Unknown</p> <p>289. Resuscitation (Excluding Bulb Syringe)</p> <p>0 None</p> <p>1 O₂ to Face</p> <p>2 O₂ with Positive Pressure</p> <p>3 Laryngoscopy</p> <p>4 Endotracheal</p> <p>5 Other (Specify) _____ 290.</p>	<p>291. Etiology of Fever in Labor (> 99.6°)</p> <p>0 No Fever</p> <p>_____ °F Highest Temp with Fever</p> <p>292</p> <p>1 Amniotitis</p> <p>2 UTI</p> <p>3 URI</p> <p>4 Unknown</p> <p>5 Other (Specify) _____ 293.</p> <p>294. Amniotitis Diagnosis by (Check All Applicable)</p> <p>0 Not Applicable</p> <p>1 Fever</p> <p>2 WBC in AF</p> <p>3 Bacteria in AF</p> <p>4 Leukocytosis - Based on WBC = _____</p> <p>295.</p> <p>5 Fetal Tachycardia</p> <p>6 Uterine Tenderness</p> <p>7 Foul Discharge</p> <p>8 Other (Specify) _____ 296.</p> <p>297. Antibiotics in Labor</p> <p>0 None</p> <p>1 Prophylactic</p> <p>2 Indicated (Explain) _____</p> <p>298 _____</p> <p>299. Type (List) _____</p> <p>300. Cord Pathology</p> <p>0 None</p> <p>1 Nuchal X1</p> <p>2 Nuchal X2</p> <p>3 2 Vessels</p> <p>4 True Knot</p> <p>5 Hematoma</p> <p>6 Vasa Previa</p> <p>7 Other (Specify) _____ 301.</p>
<p>Maternal Data</p> <p>259. VDRL Results</p> <p>0 Negative</p> <p>1 Positive</p> <p>2 Unknown</p> <p>260. Rh Factor</p> <p>0 Positive</p> <p>1 Negative</p> <p>2 Unknown</p> <p>261. Blood Type</p> <p>1 A</p> <p>2 B</p> <p>3 AB</p> <p>4 O</p> <p>5 Unknown</p>	<p>274. Fetal Distress Diagnosis By: (Check All Applicable)</p> <p>0 None</p> <p>1 Fetal Dermis PTA</p> <p>2 Fetal Dermis in Labor</p> <p>3 Cord Prolapse</p> <p>4 Scalp Ph Lowest _____</p> <p>5 Scalp pH Lowest _____ 275.</p> <p>6 Scalp pCO₂ Highest _____ 276.</p> <p>7 Meconium</p> <p>8 Monitor Tracing in Labor</p> <p>9 Positive OCT</p> <p>10 Shoulder Dystocia</p> <p>11 Other (Specify) _____ 278.</p> <p>279. Treatment of Distress (Check All Applicable)</p> <p>0 Not Applicable</p> <p>1 Untreated</p> <p>2 Oxygen by Mask</p> <p>3 Change in Position</p> <p>4 Immediate Delivery</p> <p>5 Other _____</p>	<p>328. Placental Wt. _____ gms.</p> <p>262. Birth weight _____ gms.</p> <p>263. Sex</p> <p>1 Male</p> <p>2 Female</p> <p>3 Unknown</p> <p>APGAR SCORES (Specify)</p> <p>1 Min _____ 264.</p> <p>5 Min _____ 265.</p> <p>266. Infant Outcome</p> <p>0 Alive</p> <p>1 Fetal Demise Antepartum</p> <p>2 Fetal Demise Intrapartum</p> <p>3 Immediate Neonatal Demise</p>	<p>267. If Alive, Infant Condition Prior to Transfer</p> <p>0 Satisfactory</p> <p>1 Other (Explain) _____ 268.</p> <p>269. Congenital Anomalies</p> <p>0 No</p> <p>1 Yes (Describe) _____</p> <p>270 _____</p>
<p>306. Other Comments _____</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>_____</p>			

the University of Alabama in Birmingham
the Medical Center / UNIVERSITY OF ALABAMA HOSPITALS

PAGE 4 OF 4 PAGES

INFANT SHEET

(Fill out another separate sheet for each infant)

University of Alabama in Birmingham

KEYPLATE

302. Site of Delivery

0 | | Delivery Room

1 | | Ambulance

2 | | Emergency Room

3 | | Home

4 | | Hospital - Other Rooms, Halls

5 | | Hospital - Labor Room

6 | | Private Vehicle

7 | | Unknown

303. Labor Analgesia

0 | | None

Drug	Total Dosage
304.-305. Demerol	_____mg
307.-308. Largon	_____mg
310.-311. _____	_____mg

313. Anesthesia

0 | | None

1 | | Local

2 | | Paracervical

3 | | Pudendal

4 | | Conduction

5 | | Spinal

6 | | N₂O or Penthrane Analgesia

7 | | General Endotracheal

8 | | Other _____

(Specify) 314

315. Any Anesthesia Complications

0 | | No

1 | | Yes _____

(Explain) 316.

317. Type of Delivery

1 | | Spontaneous (No manual rotation)

2 | | Spontaneous (Manual rotation)

3 | | C/S

4 | | Elective Low Forceps

5 | | Indicated Low Forceps

6 | | Indicated Mid Forceps (without Rotation)

7 | | Indicated Mid Forceps (with Rotation)

8 | | Assisted Breech Extraction

9 | | Assisted Breech Extraction with Forceps

10 | | Total Breech Extraction

11 | | Indicated Vacuum Extraction

12 | | Version and Extraction

13 | | Destructive Forceps

14 | | Other _____

Presenting Part at Delivery
(Check From Each Column)

318	319
1 Occiput	1 Anterior
2 Mentum	2 Posterior
3 Brow	3 Transverse
4 Sacrum	4 Unknown
5 Shoulder	
6 Unknown	

320. Station Immediately Prior to Forceps or C/S
(-4 to +4)

0 | | Not Applicable or _____ Station

321. If Breech (Before Attempts at Delivery)

0 | | Not Applicable

1 | | Frank

2 | | Complete

3 | | Single Footling

4 | | Double Footling

5 | | Unknown

Indications
(Check All Applicable)

322 For Forceps	323 For Total Breech Extraction
0 Not Applicable	0
1 Elective	1
2 Fetal Distress	2
3 Maternal Distress	3
4 Secondary Arrest of Descent	4
5 Aftercoming Head of Breech	
2nd Twin	5

324. Type of Forceps

0 | | None

1 | | Barton

2 | | Elliot

3 | | Kielland

4 | | Piper

5 | | Simpson

6 | | Tucker McLean

7 | | Other _____

(Specify) 325

326. Placenta

0 | | Normal

1 | | Abruptio

2 | | Accessory Lobe

3 | | Acreta

4 | | Battledore

5 | | Marginal Sinus

6 | | Percreta

7 | | Previa

8 | | Velamentous Insertion

9 | | Other _____

327. Placenta Delivery Method

0 | | Spontaneous Delivery

1 | | Expressed

2 | | Manual Removal

329. Cesarean Section

0 | | None

1 | | Low Transverse

2 | | Low Vertical

3 | | Classical

4 | | Other _____

(Specify) 330.

331. Indications for Above
(Check All Applicable)

1 | | Abruptio

2 | | Amnionitis

3 | | Breech

4 | | Cervical Cerclage

5 | | Cord Prolapse

6 | | Fetalpelvic Disproportion

7 | | Diabetes Mellitus

8 | | Elderly Primigravida

9 | | Erythroblastosis

10 | | Elective Repeat

11 | | Fetal Distress

12 | | Labor Abnormality

13 | | Malpresentation other Than Breech

14 | | Placenta Previa

15 | | Poor OB History

16 | | Positive OCT

17 | | PROM

18 | | Hypertension

19 | | Uterine Anomaly

20 | | Other _____

(Specify) 332

Primary Indication (Among Those Above)

333. _____

334. Lactation Inhibition

0 | | None with Breast Feeding

1 | | None without Breast Feeding

2 | | DeLashmone

3 | | Delestrogen

4 | | Sulfestrol

5 | | Tar

6 | | Other _____

(Specify) 335

Primary	Name _____	336 Code _____
Secondary	Name _____	337 Code _____
Attending	Name _____	338 Code _____
Med Stud	Name _____	

PS 1065

the University of Alabama in Birmingham

the Medical Center / UNIVERSITY OF ALABAMA HOSPITALS

Page 5 / MATERNAL DISCHARGE

© University of Alabama in Birmingham

FILL OUT AT DISCHARGE
(CHECK ALL APPLICABLE)

KEYPLATE

Discharge B/P _____ / _____
365 366
Last PCV Postpartum
393

394 Transfusion
0 | ☐ No
1 | ☐ Yes
341 Postpartum Hemorrhage
0 | ☐ None
1 | ☐ Uterine Atony
2 | ☐ Retained Placenta
3 | ☐ Cervix Laceration
4 | ☐ Vaginal Laceration
5 | ☐ Uterine Rupture
6 | ☐ Hematoma
7 | ☐ Other _____
(Specify) 342

343 Postpartum Infection
0 | ☐ No infection
_____ of Highest Temp
344 with infection
1 | ☐ Erythema Infection
2 | ☐ Endometritis
3 | ☐ Pyelonephritis
4 | ☐ Cystitis
5 | ☐ Wound Infection
6 | ☐ Peritonitis
7 | ☐ Septicemia
8 | ☐ Fever Unknown Etiology
9 | ☐ Atelectasis/Pneumonia
10 | ☐ Mastitis
11 | ☐ Other _____
(Specify) 345

346 Antibiotics Postpartum
0 | ☐ None
1 | ☐ Penicillin
2 | ☐ Ampicillin
3 | ☐ Gentamycin
4 | ☐ Clindamycin
5 | ☐ Cephalosporin
6 | ☐ Chloramphenicol
7 | ☐ Other _____
(Specify) 347

348 Miscellaneous Problems
0 | ☐ Normal Course
1 | ☐ Thrombophlebitis
2 | ☐ Pulmonary Embolism
3 | ☐ Coagulopathy
4 | ☐ Spinal Headache
5 | ☐ Stroke
6 | ☐ Mechanical Bowel Obstruction
7 | ☐ Ileus
8 | ☐ Wound Infection
9 | ☐ Other _____
(Specify) 349

350 Postpartum Procedures
0 | ☐ None
1 | ☐ Uterine Packing
2 | ☐ BTL Postpartum
3 | ☐ Salpingectomy
4 | ☐ Hysterectomy
5 | ☐ Appendectomy
6 | ☐ Hypogastric Ligation
7 | ☐ Curettage
8 | ☐ Ovarian Cystectomy
9 | ☐ Oophorectomy
10 | ☐ Wound Resuturing
11 | ☐ Other _____
(Specify) 351

352 Immunization
0 | ☐ None indicated
1 | ☐ Rhogam
2 | ☐ Rubella
3 | ☐ Other _____
(Specify) 353

354 Contraceptive Counseling
0 | ☐ No
1 | ☐ Yes (See below)

355 Method Chosen
0 | ☐ None Desired
Tubal Ligation
1 | ☐ Done Postpartum
2 | ☐ To be scheduled
IUD
3 | ☐ Inserted Postpartum
4 | ☐ To be done later
Oral Contraceptives
5 | ☐ Rx prev. in Hospital
6 | ☐ Oral
7 | ☐ Norinyl 150
8 | ☐ Norinyl 180
9 | ☐ Other _____
(Specify) 356
10 | ☐ To be prev. later
11 | ☐ Condoms/foam
12 | ☐ Diaphragm
13 | ☐ Other _____
(Specify) 357

363 Are Oral Contraceptives contraindicated?
0 | ☐ no 1 | ☐ yes If yes, why? _____
364

358 Discharge Medications (other than oral contraceptives)
0 | ☐ None Name Dose Schedule Duration
359, 360 Iron Sulfate _____ Mg/Day _____

383 Maternal Death
0 | ☐ No
1 | ☐ Yes (Explain) _____
384

Followup Needed
375. ☐ Routine
at _____ clinic in _____ wks
380. 381
If not routine, explain problem
376. _____
Place _____ wks
377. _____
Place _____ wks
378. _____
Place _____ wks
379. _____
Place _____ wks
Mo Day Yr
387 Date of Discharge _____

389 Other Comments

Current Information
509 Phone _____
511 St. _____
512 City _____ 514 Zip _____

Primary _____ Name _____ 390
Secondary _____ Name _____ 391
Attending _____ Name _____ 392
Next Stud _____ Name _____

the University of Alabama in Birmingham
the Medical Center / UNIVERSITY OF ALABAMA HOSPITALS
 DISCHARGE FORM

Key Plate

NAME: _____ HOSP. NO.: _____ ROOM: _____
 SURG.: _____ ASSIST: _____
 DATE OPER. OR E.D. VISIT _____ ADMITTED: _____ DISCHARGED: _____
 DOCTOR/SERV.: _____ DICTATED: _____ TRANSCRIBED: _____

1 DIAGNOSIS

PROCEDURES

- 2 1. Mature/Premature/Post-term Birth, Living Child
- 3 2. Appropriate/Small/Large Size for Gest. Age
- 4 3.
- 5 4.
- 6 5.
- 7 6.

8 ADMISSION HISTORY: This _____ gm White Female twin # born at _____ hrs.,
 9 Black Male singleton
 10 is a product of a _____ y/o F _____ P _____ A _____ L _____ following a _____ wk gestation.
 11 Apgar 1' _____ Pregnancy:
 12 5' _____ Labor
 13 Resus- _____ None _____ abn FIT:
 14 citation _____ 0₂ to face _____ meconium:
 15 _____ 0₂ by Pos Pres _____ Delivery:
 16 _____ intubated
 17 _____ drugs(specify) _____

19 ADMISSION PHYSICAL EXAM: _____ NORMAL _____ ABNORMAL _____ Gestational Age _____ Wks.
 20 COMMENTS: _____

Congenital Anomalies:

- 1.
- 2.

24 HOSPITAL COURSE: _____ NORMAL _____ ABNORMAL _____

27 DISCHARGE PHYSICAL EXAM: _____ NORMAL _____ ABNORMAL _____ DISCHARGE WEIGHT: _____
 28 COMMENTS: _____

31 LABORATORY DATA: RF _____ IFA TOXO _____ VDRL _____
 32 MAXIMUM BILIRUBIN: Indirect _____ Total _____

33 OTHER:

34 Blood Type: _____
 35 Rh: _____
 36 Coombs': _____

36 DISPOSITION: WELL BABY CLINIC: _____; CHILDREN'S CLINIC _____; PRIVATE: _____
 39 Followup in _____ week(s) _____ Family Practice Center

41 OTHER: Breast/Bottle Feeding

43 MEDS: 1.
 44 2.
 45 3.

_____, M.D.

SCHOOL OF PUBLIC HEALTH
UNIVERSITY OF ALABAMA AT BIRMINGHAM
DISSERTATION APPROVAL FORM

Name of Candidate Richard Sinsky

Major Subject Public Health (Epidemiology)

Title of Dissertation An Epidemiologic Investigation of the Possible
Association Between Maternal Diabetes and Maternal Hypertension
and Placental Infection with Ureaplasma Urealyticum

Dissertation Committee:

Rodney C. Ho, Chair

Paul H. Cassell

Robert W. Anderson

Laura Parker

Gymne Wagenknecht

Shirley Cole

Department Chair

W. H. Hest

Academic Affairs Dean

Ch. C. C. C.

Dean, School of Public Health

Date

3-9-92

Date

1-10-97

Date